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One of a large number of mutant mice used in immunological research, the
"motheaten" mouse was the first model of a specific protein tyrosine phosphatase
deficiency. Mice carrying one of two allelic mutations at the "motheaten" locus have
severe systemic autoimmunity and immune dysfunction as a result of mutations in the
hematopoietic-cell phosphatase (Hcph) gene, which encodes the protein tyrosine
phosphatase SHP-1. Studies using "motheaten" (me/me) and "viable motheaten"
(mev/mev)mice have increased the understanding of numerous signaling pathways in
immune and hematopoietic cells. A number of studies on SHP-1 function in normal and
pathologic states are described here.
Homozygous mev/mevmice have an increased percentage of autoantibody
associated B-1 B-cells that express the cell surface glycoprotein CD5. To investigate the
hypothesis that absence of CD5 in mev/mevmice will result in decreased systemic
autoimmunity, we created a stock of ~~5""me'/rne' mice. These mice have a longer
lifespan than mev/mevmice, associated with reduced pulmonary inflammatory disease,

splenic macrophage numbers, and serum IgM levels. However, autoantibodies against
dsDNA and histone proteins were not significantly reduced. These studies suggest that
CD5 expression is not required for autoantibody production, but otherwise indicate a role
for CD5 in the development of irnrnunopathologic lesions in mev/mevmice.
Dysregulated macrophage populations in mev/mevmice presumably have
secondary effects on other cell types. To examine these effects, as well as the primary
results of SHP-1 deficiency in macrophages, we developed a stock of mice transgenic for
a dominant-negative form of SHP-1, under control of a macrophage specific promoter.
The catalytically inactive dominant-negative protein should occupy SH2 binding sites,
blocking the recruitment of functional wild-type SHP-1.

SHP- 1 plays a putative role in oncogenesis. To substantiate this role, we have
monitored tumor development in aged +/me and +/mev mice. Preliminary studies do not
support the hypothesis that a spontaneous chondroblastic osteosarcoma that occurred in
an aging +/mev mouse was caused by loss of SHP- 1 expression. Nonetheless, we
describe the transplantable cell-line derived from this tumor, which mimics the process of
endochondral ossification in vivo and is a potentially valuable model for studies of
osteosarcoma and bone biology.
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Chapter 1
THE MOLECULAR BASES OF SPONTANEOUS IMMUNOLOGICAL
MUTATIONS IN THE MOUSE AND THEIR HOMOLOGOUS HUMAN
DISEASES '

Introduction
Spontaneous genetic mutations that disrupt development or regulation of the
immune system in inbred mouse strains provide unique models for the study of immune
deficiency and autoimmune diseases of humans. While these mouse mutations have been
widely utilized to increase our understanding of the immune system in normal and
pathological states, recent determination of the molecular bases of many of these
mutations has provided even deeper insight into the underlying biology and biochemistry
of the mammalian immune system. A number of the mouse genes disrupted by
spontaneous mutation have human homologues, and mutations in many of the human
genes result in immunological diseases. In these cases, immunological mutations in mice
provide an especially valuable resource to study mechanisms of disease and to investigate
experimental interventions that may lead to treatments for the human disease.
In recent years, advances in transgenic and gene targeting technology have
allowed generation of mice with genetic alterations specifically targeted to selected genes
or regions of genes, allowing focused analysis of their products and functions. While
these technologies have become powerful tools for scientific research, they commonly
rely on identification and cloning of a gene prior to creating a targeted mutation of that

gene. While targeted mutation of a specific gene often results in an imperceptible or
unexpected phenotype, spontaneous mutants are selected by discemable phenotypes of
interest. Investigation into the genetic basis of many of these spontaneous mutations has
led to the identification of previously unknown, novel genes.
The intent of this review is not to provide exhaustive detail about the phenotypes
of mutant mice. The phenotypes of many of these mutants have been reviewed
previously (I), and references to available reviews specific to each mutant will be
provided. This review has been written as an overview of spontaneous mouse mutations
resulting in immunodeficient or autoimmune phenotypes that have been defined at the
molecular level (summarized in Table 1.1). Human diseases with homology to these
mouse mutations are discussed, and the uses of these mice in research on human disease
and immunobiological function are also discussed (summarized in Table 1.2).
Genetic nomenclature can be complex. Gene symbols are changed as loci are
identified at the molecular level and gene families are determined. The current approved
symbol for each mouse gene is provided in the heading for the individual mutations, as
well as in Table 1.1. The symbol for the homologous human gene is provided in Table
1.2, and is included in the text. General background of nomenclature changes is provided
in the text, and the most commonly known name for each gene and mutation is used in
subsequent discussion.

Based on: Joliat MJ,Shultz LD. 2001. The molecular bases of spontaneous immunological mutations in
the mouse and their homologous human diseases. (Review) Clin. Immunol. lOl(3):1 13-129.

Table 1.1. The molecular bases of spontaneous immunological mutations in the mouse.
Allele Name
(Original Symbol)
severe combined
immunodeficiency
(scid)

Gene
Symbol
Prkdc

nude (nu)

Foxnl

Gene Name
DNA activated
protein kinase,
catalytic subunit

Mouse
Chr
16

Phenotype
Severe immune deficiency
caused by absence of both B and
T cells, radiosensitivity

forkhead box nl
(forkheadwinged
helix family of
transcription factors)

Hairless, athymic, T-cell
deficiency

forkhead box P3
(forkheadwinged
helix family of
transcription factors)

Thrombocytopenia, increased
numbers of CD4+/CD8- T
lymphocytes, extensive multiorgan infiltration, and elevation
of numerous cytokines

hematopoietic cell
phosphatase

Severe immune deficiency,
autoimmunity, x-ray resistance

(lpr)

tumor necrosis family
receptor superfamily,
member 6

Lymphadenopathy,
autoimmunity

generalized
lymphoproliferative
disease (gld)

tumor necrosis factor
superfamily, member
6

Lymphadenopathy.
autoimmunity

kit oncogene (stem
cell factor receptor)

Defects in pigment forming cells,
RBC's, mast cells and progenitor
cells, impaired resistance to
parasitic infection

kit ligand (stem cell
factor)

Severe macrocytic anemia, mast
cell deficiency

Bruton's
agammaglobulinemia
tyrosine kinase

Defective immune response to
type 11 thymus-independent (TI11) antigens, impaired immune
response to some thymusdependent (TD) antigens, and
impaired lymphocyte response to
B-cell mitogens

mitogen-activated
protein kinase kinase
kinase 14

Absence of lymph nodes and
Peyer's patches

scurfy (sj)

motheaten (me),

Hcph

lymphoproliferation

dominant spotting

Kit

(w)

steel (sl)
X-linked
immunodeficiency
(xi4

alymphoplasia (aly)

Btk

Allele Name

Gene
Symbol
Lyst

Gene Name
lysosomal trafficking
regulator

Mouse
Chr
13

Phenotype
Abnormal giant lysosomal
granules in granule containing
cells, defective granulocyte
activity, NK cell deficiency,
platelet storage pool deficiency

osteopetrosis (op)

colony stimulating
factor 1
(macrophage)

Osteoclast defects, macrophage
deficiency, monocytopenia,
defective bone remodeling

defective
lipopolysaccharide
response (48)

toll-like receptor 4

Defective response to bacterial
endotoxin. Increased
susceptibility to Gram-negative
infection.

microphthalmia (mi)

microphthalmia
associated
transcription factor

Developmental defects in
melanocytes, osteoclasts and
mast cells

wasted (wst)

eukaryotic translation
elongation factor 1
alpha 2

Tremor, progressive paralysis,
lymphoid hypoplasia, death by
30 days of age

hairless (hr)

hairless

High incidence of early onset
leukemia, low cellular immune
response, deficiency of splenic
THcells.

Table 1.2. Human homologous diseases and uses of mouse models in the study of human
disease and irnrnunologica~function.
Mouse Mutation

Human
Gene

Human Disease Homologues and Uses in Research on Human
Diseases

severe combined
immunodeficiency

Mutations in the human PRKDC gene have not been found associated
with human SCID or any other disease. However, scid mice are
widely used as hosts for normal and malignant human cells. They are
also used as a model to study combined immune deficiency in
humans and as a tool to decipher the normal biological role of DNAPK.

nude

A mutation in this gene has been found in a family in Italy resulting
in immune deficiency with absence of thymus and hair (OMIM
601705). These mice also serve as hosts for human solid tumors.

scurfy

Mutations in FOXP3 are associated with the X-linked syndrome of
immunodysregulation, polyendocrinopathy and enteropathy (IF'EX)
(OMIM 304930). May be used to study autoimmune disease
development and molecular mechanisms involved in T cell
regulation.

motheaten

No diseases are known to result from heritable mutations in PTPN6.
Somatic mutations in this gene and defective gene expression have
been associated with myeloid leukemia, T-cell lymphoma,
polycythemia Vera and breast cancers. Motheaten mice are also used
to study the normal function of the SHP-1 phosphatase in the immune
system.

lymphoproliferation

Mutations in TNFRSF6 and TNFSF6 are associated with autoimmune
lymphoproliferative syndrome 1A (ALPS1A-also called CanaleSmith syndrome) and ALPSIB, respectively (OMIM 601859).
Spontaneous somatic mutations in TNFRSF6 have been found in
cases of T-cell leukemia, multiple myeloma and non-Hodgkin's
lymphoma. Study of these mice can also provide insights into the
death receptor mediated system and its role in human disease.

generalized
lymphoproliferative
disease

Germ line mutations in KIT have been found to cause human
piebaldism (OMIM 172800). Somatic mutations, many of which
cause constitutive activation of KIT, have been associated with mast
cell neoplasia, cutaneous mastocytosis and tumors of the
gastrointestinal stroma in humans.

dominant spotting

steel

X-linked
immunodeficiency

BTK
(ChX)

Bruton's X-linked agamrnaglobulinemia (XLA) (OMIM 300300) is
caused by a variety of mutations in BTK. Mice with the xid mutation
are also valuable tools for investigation of B cell-lineage development
and signaling.

Mouse Mutation

Human
Gene

Human Disease Homologues and Uses in Research on Human
Diseases

alymphoplasia

There are no known human diseases caused by mutations in
MAP3K14. Mice homozygous for the aly mutation are valuable tools
in the study of inflammatory processes involving NF-K-Binduction.

beige

The bg mouse is the homologue of human Chediak-Higashi syndrome
(OMIM 214500). Studies using the bg mouse may contribute to the
understanding of the accelerated phase of Chediak-Higashi syndrome
by helping to reveal the role of CTLA4 in T-cell regulation and
lymphoproliferation.

osteopetrosis

Osteopetrosis in humans has not been found associated with
mutations in CSFI. However, op mice are a valuable resource in the
study of osteopetrotic diseases and have contributed significantly to
the understanding of normal bone biology

defective
lipopolysaccharide
response

Mutations in TLR4 have been associated with reduced response to
' may
inhaled LPS in humans. Study of mice carrying the L ~ ~ Callele
lead to new approaches in the treatment of septic shock, endotoxin
induced airway inflammation and other endotoxin mediated diseases.

microphthalmia

Mutations in MITF are associated with Waardenburg Syndrome type
2 (WS2) (OMIM 193510) and Tietz syndrome (OMIM 103500).
Studies of mi mice can provide insights into mechanisms of
melanocyte signaling and development.

wasted

There are no human diseases known to be related to mutations in
EEFIA2. Studies of wst mice have revealed mechanisms in the
developmental regulation of protein translation.

hairless

Mutations in the human HR gene are associated with congenital
atrechia with papules (OMIM 209500).

S~ontaneousImmunological Mutations in the Mouse
Severe combined immune deficiency (~rkdc"'~)
In 1983, Bosma et al. (2) reported a mutation (scid) in a colony of C.B-17 mice
whose phenotype resembled human severe combined immune deficiency (SCID).
Homozygosity for the scid mutation results in a deficiency of T and B lymphocytes with
accompanying hypogammaglobulinemia and absence of both humoral and cell-mediated
immune function (reviewed in (3)). Although C.B-17-scid mice have defects in adaptive
immunity, many aspects of their innate immune function are unaltered ((4) and included
references). C.B-17-scid mice have been widely used as hosts for human
hematolymphoid cells, but intact innate immunity prevented long term survival of these
cells. Backcrossing of the scid mutation onto the NODJLt strain background, which
confers multiple defects in innate immunity, provided a scid mouse model in which
survival of transplanted human cells was significantly increased (4). NODILtSz-scid
mice are now a commonly used host for normal as well as malignant human
hematolymphoid cells in many areas of research.
The scid mutation results in failure of V@)J recombination (5-8) and also causes
a defect in DNA double-strand break @SB) repair (9, lo), which leads to increased
radiosensitivity (1 I). These observations preceded the discovery that the mutation
causing the scid phenotype was within the gene encoding the catalytic subunit of a DNAdependent protein kinase (DNA-PK,) (12), now given the formal gene symbol Prkdc.
DNA-PK is a serinelthreonine protein kinase composed of the catalytic subunit as well as
a regulatory component, the Ku701Ku80 heterodimer, which binds DNA ends. DNA-PK
plays a role in non-homologous end joining and is essential to the proper functioning of

the mechanisms of DSB repair and V@)J recombination as well as a number of other
processes (for review, see (13)).
Mutations in DNA-PKcs have been associated with SCID in both Arabian foals
(14) and Jack Russell terriers (15). However, of the many severe combined immune
deficiencies known in humans, none have yet been associated with mutations at the
human PRKDC locus. The severity of V@)J recombination defects in animals with
DNA-PKcs mutations correlates with the normal enzymatic activity of DNA-PK in the
species (15). Genetic DNA-PKcs deficiency causes a severe V@)J recombination deficit
in horses, which have relatively high normal DNA-PK activity. The level of DNA-PK
activity in humans is many times higher than that of horses, suggesting that humans may
have a profoundly severe phenotype as a result of a genetic DNA-PKcs mutation. It is
possible that a gennline mutation in PRKDC would be lethal (15). DNA-PKcs defects in
mice, in which DNA-PK activity is relatively low, cause a less severe V@)J
recombination deficit than in humans or horses. Nonetheless, in addition to being
important tools in hematology, cancer and AIDS research, mice homozygous for the scid
mutation are a valuable models for the study of combined immune deficiency and for
investigation of the normal biological role of DNA-PK in non-homologous end joining.
Analysis of the differential requirement for DNA-PKcs between species may reveal
important insights into the mechanisms of V@)J recombination and DSB repair.

Nude (Fomzl""l
The nude (nu) mutation was first reported in 1966 as an autosomal recessive
mutation that resulted in hairlessness and failure to thrive (16). In 1968, Pantelouris (17)

observed that nu mice were congenitally athymic and exhibited leukopenia. Extensive
studies in many laboratories have utilized these T-cell-deficient mice to examine the roles
of T-cells in host defense against pathogens and in immune responses to various antigens.
The mouse nu mutation is within a gene encoding a forkheadwinged helix
transcription factor (18). Members of this family of transcription factors are involved in
gene regulation during embryological development and cell differentiation (19). The
disrupted gene responsible for the nu phenotype was originally designated as whn
(winged-helix-nude), but was renamed H f h l l and, more recently, Foxnl to comply with
unified nomenclature designation for forkheadwinged helix transcription factors (20). A
second mutation at the nude locus, named 'streaker' (nu"?, occurred in an inbred colony
of AKRfJ mice (21,22). The phenotype of these mice resembles that of nu mice and the
symbol for the mutation has been designated Foxnl""". Mutations in homologous genes
have also been reported in rats (23) and guinea pigs (24). Foxnl is expressed specifically
in the epithelial cells of the thymus and skin (18). Thus, the T cell deficiency seen in nu
mice is a result of a defective thymic microenvironment rather than intrinsic defects in T
cell progenitors.
Mice carrying the nu mutation are valuable tools for cancer research since they
serve as experimental hosts for certain human neoplasms (25) (for review, see (26)).
However, mice with the scid mutation are now recognized as a more appropriate model
for studying human tumor biology than nu mice. Nude mice lack mature T cells, but they
do have functional B cells and circulating immunoglobulin, as well as high levels of NK
cell activity, which can prevent the growth of certain tumors. Many tumors, particularly
those of hematopoietic origin, grow better in scid mice, which lack both B and T cells.

Some solid tumors, however, such as mammary cancers, appear to grow equally well in
nu and scid mice, and thus nu mice are still a commonly used model in studies of solid

tumor biology and experimental therapy (27,28).
The nu mouse was originally proposed as a model for DiGeorge syndrome in
humans, but this mutant lacks certain characteristics of DiGeorge syndrome, such as
parathyroid hypoplasia and cardiac anomalies. DiGeorge syndrome has since been found
to be due to deletion of a region of human chromosome 22q11, which contains a number
of genes that may be responsible for the syndrome (29). Recently, a nonsense mutation
in exon 5 of the homologous human gene, termed winged helix nude (WHN), was
reported in a family in Italy (30,3 1). Two sisters presented with a phenotype of impaired
T-cell function, alopecia, nail dystrophy and absence of a thymic shadow. This rare
condition is an interesting example of how a mutation in a gene not expressed in
hematopoietic cells can result in an immunodeficiency disease in humans.

Scurfy (FoxpYf'l
The scurfy (sf) mutation was first reported in 1959 (32) and further described in the early
1990's (33-35). Scurfy is an X-linked mutation characterized by anemia,
thrombocytopenia and a lymphoproliferative disorder that results in splenomegaly,
hepatomegaly, and enlarged lymph nodes. These pathologic changes are accompanied by
diarrhea, exfoliative dermatitis and runting (33,34). Hernizygous males have an average
lifespan of 24 days (33). The lymphoproliferative disease in sf mice is mediated by
CD4TD8- T lymphocytes (36,37), and involves over-expression of a variety of cytokine
genes (38,39).

The sf mutation was at one time proposed to be a model for human WiskottAldrich syndrome (WAS) ( 3 9 , because sf and WAS map to homologous regions of the
mouse and human X chromosomes (40,41). However, sf has recently been identified as
a mutation in the Foxp3 gene, which encodes a novel forkheadwinged helix transcription
factor called scurfin (42). Although the phenotype of sf mice clearly demonstrates the
requirement of the scurfin protein for normal T cell function, the precise role of this
transcription factor and the mechanisms that regulate its expression have not yet been
elucidated.
The growing family of forkheadwinged helix transcription factors contains many
members that are highly conserved between species (19,20,43). The human homologue
of the mouse scurfin gene has been identified. Mutations in this gene, FOXP3, have been
found associated with a human X-linked syndrome of immune dysregulation,
polyendocrinopathy and enteropathy called IPEX (44-46) (for review, see (47)). IPEX is
a frequently fatal disease of childhood that shares many of the phenotypic characteristics
of the sf mouse (48). Patients suffer from insulin-dependent diabetes mellitus (IDDM),
hypothyroidism, immune thrombocytopenia, and eczema. There are currently no
treatments shown to have long-term success in IPEX patients (49). The mouse sf
mutation provides a valuable model for the study of this severe human autoimmune
disease and may assist in the development of immunological therapy. Studies of these
mice may also offer further insights into the molecular mechanisms involved in the
regulation of T cell function in the normal human immune system.

Lymphoproliferation !~nfr@5'~?
and generalized lymphoproliferative disease ( ~ n f ~ f 6 ~ ' ~ )
Mice homozygous for the lymphoproliferation (Ipr) and generalized
lymphoproliferative disease (gld) mutations share nearly identical phenotypes,
characterized by systemic autoimmunity and massive T-lymphoid hyperplasia.
Accompanying polyclonal B cell activation results in hypergammaglobulinemia and high
levels of autoantibodies against a variety of autoantigens in both Ipr and gld mice,
contributing to the development of immune complex glomerulonephritis. Both T- and Blymphocyte populations of Ipr and gld mice are deficient in their responses to exogenous
immune stimuli (50, 51) (for review, see (52)).
The Ipr mutation arose during the development of the MRLMpJ inbred strain,
and was first reported in 1978 (50,53) as a model of systemic lupus erythematosus
(SLE). MRL wild type mice do not exhibit lymphoproliferation, but do develop SLE-like
symptoms at about two years of age, leading to the original hypothesis that the Ipr
mutation may act only to accelerate the development of autoimmune disease in strains
already prone to autoimmunity. Although transfer of this mutation to a variety of inbred
backgrounds lacking a predisposition to autoimmunity results in lymphadenopathy and
autoimmunity, the severity of disease varies depending on the genetic background of the
strain (54). MRWMpJ mice are the most severely affected by the Ipr mutation;
homozygotes die by 6 months of age.
The observation that neonatal thymectomy significantly reduces autoimmune
disease and lymphadenopathy in Ipr mice (55) was followed by the discovery that the Ipr
mutation caused the aberrant expansion of an abnormal population of CD4- CD8- (double
negative, DN) T cells (56). Approximately a decade later, the lpr mutation was found to

be in the gene encoding the Fas antigen (also called CD95 or APO- I), a widely expressed
cell surface protein that mediates apoptosis and is involved in the negative selection of
autoreactive T cells in the thymus (57, 58). Fas shares structural homology with the
tumor necrosis factor receptor family, and the gene has since been renamed 'Tumor
necrosis factor receptor superfamily, member 6' or Tnfrsfs. A new allele at the lpr locus
was reported in 1990, termed lpf (59), resulting in a phenotype similar to the lpr
mutation. The lpr mutation results in the absence of cell surface Fas, while the lpfg
mutation results in expression of a non-functional receptor (60). The gld mutation, which
produces a phenotype similar to lpr, occurred in a colony of C3HlHeJ inbred mice (5 1,
61). The gld mutation was found to be the result of a point mutation in the gene encoding
the ligand for Fas (Fasl, CD95L) (62), now termed 'tumor necrosis factor superfamily
member 6' (Tnfsm.
Fas mediated apoptosis is crucial to the proper development and function of the
immune system (see review (63)). Studies of lpr and gld mice have provided valuable
insights into the death receptor mediated system and its role in human disease (for review
see (64)). In humans, mutations affecting both Fas (TNFRSF6) and Fas ligand (TNFSF6)
are associated with Autoimmune Lymphoproliferative Syndrome (ALPS), a childhood
dsease characterized by lymphadenopathy and autoimmunity. Mutations of TNFRSF6
are commonly associated with a form of ALPS called ALPSlA, also known as CanaleSmith syndrome (65-68). A mutation of TNFSF6 was discovered in a screening of SLE
patients (69). This patient had lymphoproliferative disease as well as symptoms of SLE,
and the case was later designated as an alternative form of ALPS, called ALPSlB (70).
Somatic mutations of Fas have also been associated with a number of human

malignancies including T-cell leukemia (71,72), multiple myeloma (73), and nonHodgkin's lymphoma (74) (for review, see (75)).

Dominant white spotting it^) and steel { ~ i t l ~ ' )
Mutations at the dominant white spotting (W) (76,77) and steel (Sl) (78) loci
affect the development of hematopoietic precursor cells, mast cells, neural crest-derived
melanocytes and germ cells. Consequences of these developmental abnormalities include
macrocytic anemia, mast cell deficiency, pigmentation abnormalities and infertility
(reviewed in (79)). There are a number of alleles at both the W and Sl loci, resulting in
diverse phenotypic effects that vary in severity from embryonic lethality to mild anemia
with survival to adulthood (79-81)
Although the phenotypes of Wand Sl mutant mice are similar, numerous early
studies indicated that the sl mutation affected the extracellular microenvironment, while
the W mutation was within a gene expressed by the affected stem cells themselves (8286). The genes disrupted by these two mutations were found to encode a growth
factorlreceptor pair essential to a variety of developmental processes. The W mutation
affects the Kit proto-oncogene (also known as c-Kit), which encodes a transmembrane
receptor tyrosine kinase, KIT. (87, 88). The steel mutation affects the gene encoding
stem cell factor (SCF) (also called mast cell growth factor, kit-ligand or steel factor,
current approved gene symbol: Kitl), which is the ligand for KIT (89-92) (see review
(93)).
KIT is expressed at various levels on a wide variety of cell types. SCF (Kitl) is
expressed on stromal cells, fibroblasts and endothelial cells, and is found at low levels in

the circulation. This growth factor/receptor system has been implicated in a wide variety
of processes, from promotion of hematopoietic cell survival and proliferation to
mediation of cell migration and adhesion (for review, see (94-97).
In humans, heritable mutations in the homologue of the mouse Kit gene, KIT,
have been found to cause piebaldism (98,99), a genetic disorder resulting in patches of
white skin and hair due to a disorder in melanocyte development. In contrast to the W
mouse, individuals affected by piebaldism exhibit no apparent defects in mast cell
function nor do they develop anemia as a consequence of the KIT mutation.
Spontaneous, non-familial mutations in the KIT gene have been found in cases of human
mast cell neoplasia and cutaneous mastocytosis (100, 101), as well as in tumors of the
gastrointestinal stroma (102, 103). These mutations often cause constitutive activation of
KIT (for a review of KIT activating mutations, see (104)). No mutations have been
found in KITLG, the human homologue of the mouse stem cell factor gene.

X-linked immune deficiency ( ~ t k " ~ )
X-linked agammaglobulinemia (XLA) in humans was first reported as a primary
immunodeficiency disease in 1959 (105). XLA patients have severely decreased levels
of mature B lymphocytes, dramatically reduced levels of serum immunoglobulin (Ig) and
are highly susceptible to bacterial infections (105, 106). Many years later, the X-linked
immune deficiency (xid) mutation was observed in the CBAIN mouse strain, resulting in
a disease with characteristics similar to, but less severe than human XLA (107-1 11).
Peripheral B cells in xid mice are moderately reduced in number, and those present
display a primarily immature phenotype. Mouse xid is also characterized by impaired

signaling through a variety of B-cell surface receptors, absence of peritoneal B-1 cells,
reduced levels of serum IgM and IgG3 and failure to respond to type II thymusindependent (TI-II) antigens (reviewed in (1 12)).
The mutations causing both the human and mouse chseases lie within the
respective genes encoding a cytoplasmic protein-tyrosine lunase, coined Bruton's
agarnmaglobulinemia tyrosine kinase (Btk) (1 13-116). Btk is a member of a growing
family of homologous tyrosine kinases (reviewed in (1 17, 118)). Although Btk appears
to function primarily in the B-cell lineage, in development and expansion of early B cells
and in survival and activation of mature B cells, this tyrosine lunase is expressed in
erythroid progenitors and monomyeloid cells in adchtion to B cells (1 13, 114). Btk is not,
however, expressed on T or NK cells. Mouse xid results from a specific rnissense
mutation in Btk affecting the pleckstrin homology (PH) domain of the BTK protein (1 15,
116).
Human XLA has been found associated with an extensive variety of BTK
mutations in affected individuals (1 19). A comprehensive database of these mutations
has been established to assist clinicians and researchers in their study of the disease
(120). Efforts have been made to relate the specific BTK domain mutated to the severity
of the phenotype in humans but no definitive connections have been drawn. The
presence of phenotypic variation in XLA, even among affected individuals with identical
genetic abnormalities, highlights the existence of modifier genes affecting B cell
development. Mochfier genes, or some differential requirement for the BTK protein
between species, is the likely cause of the disparity of disease severity between mouse
and human, as well. Human BTK mutations that are almost identical to mouse xid do not

result in a milder XLA phenotype than other BTK mutations. Moreover, mice with a
targeted null mutation of Btk have a phenotype similar to that of xid mice (121, 122),
reaffirming that absence of BTK function, not the nature of the mutation, results in the
species specific B-cell defects seen in XLA patients and xid mice. The BTK gene is
involved in a wide array of complex functions. Studies of the disease variations between
mouse and human and among individual human XLA patients have contributed to the
elucidation of the role of BTK in B cell development and signaling and revealed insights
into other pathways involved in B cell function. These discoveries have been the subject
of a number of recent reviews (123-126). New techniques of identifying BTK mutations
in humans have also led to the identification of several other genetic B lineage defects
(127).

Alym~hoplasia!~ap.?k14"'~)
Alymphoplasia (aly) mutant mice are homozygous for an autosomal recessive
mutation resulting in absence of lymph nodes and Peyer's patches, structural defects in
the spleen, and impaired antibody and cell-mediated immune responses (128- 130).
Recent studies have shown that in addition to structural defects in secondary immune
organs, aly mice have intrinsic defects in both B and T cells (131, 132). Thus, the
abnormal immune function seen in these mice appears to be due to both stromal
insufficiency and an innate defect in lymphocyte function.
Recently, Nuclear Factor (NF)-K-B-inducingkinase (Nik) was identified as the
mutated gene responsible for the aly mutation (133). A member of the mitogen activated
protein kinase family (134), the Nik gene has since been renamed Map kinase kinase

kinase 14 (Map3k14) (81)to comply with evolving standard nomenclature. The NIK
protein is a serinelthreonine kinase involved in the induction of NF-K-B through a
number of different cytokine receptors (134). The mutation in aly mice encodes a defect
within the carboxyl-terminal interacting domain of NIK, disrupting its ability to associate
with the adaptor proteins that target its activity, while leaving its kinase region intact

(133).
The mechanisms through which NIK functions in cytokine signaling and how the
functional NIK deficit seen in aly mice could result in their characteristic phenotypic
defects are unclear. While it is widely accepted that NIK stimulates NF-K-Bactivity, the
receptors that the kinase conveys signals through have not been fully clarified (134-137).

NF-K-Bis a transcription factor that is induced by many cytokines and regulates the
expression of a large number of immune and inflammatory genes (138, 139). In the
original report of the discovery of the NIK protein, NIK was implicated in NF-K-B
induction through TNF receptors, CD95 and IL-1 (134). A recent study using mice
carrying a targeted deletion of the NIK gene contradicts these findings and implicates

NIK in regulation of signaling through the lymphotoxin-f3receptor (137). Although the
NIK deficient mice used in this latter study have a complete absence of NIK protein
whereas aly mice produce normal levels of a mutated NIK protein, their phenotypes are
almost identical.
The human NIK gene was considered an interesting positional and biological
candidate for frontotemporal dementia with parkinsonism linked to Chromosome 17

(FTDP-17) (OMIM 600274) (140). However, mutational screening has not revealed
concomitant mutations of the NIK gene with FTDP-17 (140). Mutations in the gene

encoding microtubule-associated protein tau (MAPT) have since been found associated
with some cases of FTDP-17 (141). There are currently no known human diseases
caused by mutations in the NIK gene. However, X-linked anhidrotic ectodermal
dysplasia with immune deficiency (EDA-ID) (OMIM 300291) has recently been reported
to be associated with mutations in the gene IKBKG (142), which encodes a protein (IKKy, NEMO, FP-3) that interacts with the NIK protein (143) and is involved in regulation

of NF-K-B activation. Mutations in IKBKG cause impairment of NF-K-Bsignaling which
results in EDA-ID. In addition, a number of inflammatory diseases including rheumatoid
arthritis, asthma and multiple sclerosis are associated with enhanced NF-K-Binduction.

Studies of aly mice will continue to contribute to the understanding of the complex
signaling pathways involved in NF-K-Binduction in hematopoietic cells. Clarification of
these pathways will provide further insight into the inflammatory process, assisting in the
development of novel therapies for a diverse range of inflammatory diseases.

Beige ( L ~ S ~ ~ )
The beige (bg) mutation was first identified as a coat color mutation that resulted
in large, abnormal granules in all granule containing cells, including granulocytes and
melanocytes (144, 145). In addition to abnormal hair pigmentation, bg mice have
defective cytotoxic T cell responses and a deficiency in NK cell function. Beige mice
display increased susceptibility to infection by a number of pathogens, including
cytomegalovirus (146) and Mycobacterium avium (147). These mice also exhibit a
reduced ability to reject transplanted tumors and have a bleeding disorder due to a platelet
storage pool deficiency (148). Characteristic features of the bg mutation are also found

in Chediak-Higashi Syndrome (CHS) in humans (145, 149) and in a similar disease
described in a number of other mammals, including mink, cattle, cats and killer whales
(150). There are also a number of different alleles of bg resulting from distinct
spontaneous mutations in the mouse (81).
Complementation analysis had suggested that the same gene was responsible for
mouse bg, human CHS and CHS-like disease in other species (151). Two groups
independently identified the mouse bg gene (152, 153), which encodes a widely
expressed cytosolic protein implicated in the regulation of lysosomal fission (154) and
has been designated the lysosomal trafficking regulator gene (Lyst). Identification of the
mouse bg gene led to the discovery of a novel human gene with significant sequence
homology to the mouse gene (153, 155). Sequencing of the human gene, currently called

CHSI, revealed the presence of mutations in several CHS patients (153, 155).
Subsequent studies confirmed that the homologous gene was responsible for the CHSlike disease in rats (156) and cows (157). The precise function of the CHSIbeige protein
is not yet clearly understood. Two recent reviews contain useful background information
and summaries of the current knowledge in the field (148, 158).
The disease phenotype seen in bg mice and human CHS patients is remarkably
similar. However, CHS patients commonly develop a lymphoproliferative disorder
termed the 'accelerated phase' of the disease, which does not occur in bg mice. It has
recently been reported that intracellular trafficking of CTLA-4 (CD152) is defective in
CHS patients (159). CTLA-4 is a negative regulator of T cell activation, and the
decreased expression of this molecule on T cells of CHS patients may disrupt T cell
homeostasis resulting in the lymphoproliferative syndrome. CTLA-4 trafficking in bg

mice is relatively unaffected. Therefore, the absence of the lymphoproliferative disease
in bg mice may be a function of species-specific variations in intracellular processing of
the CTLA-4 protein.

Osteopetrosis !C?floP)
Mice homozygous for the osteopetrosis (op) mutation are small in size and
toothless, with a shortened lifespan and reduced fecundity. They have a severe osteoclast
deficiency and exhibit defects in bone remodeling (160). The op mutation affects the
development and differentiation of most macrophage subpopulations, resulting in reduced
numbers of osteoclasts as well as tissue macrophages in op mice (161), functional deficits
in peritoneal macrophage populations (162, 163) (reviewed in (164)) and phenotypic
abnormalities in dendritic cells (165). Due to reduction of marrow cavity volume, bone
marrow hematopoiesis in op mice is severely reduced (162), and compensatory
extramedulary hematopoiesis is seen in both spleen and liver (166).
Transplantation of bone marrow or spleen cells from wild type mice does not
rescue the osteopetrotic phenotype of op mice (167). This observation suggested that the
op defect was in the stromal microenvironment rather than the hematopoietic stem cells
themselves, and led to the discovery that the op mutation is a single base change in the
macrophage colony stimulating factor gene, Csfl (168). This gene encodes macrophage
colony stimulating factor (CSF-1, also called M-CSF), which is a cytokine involved in
regulating osteoclastogenesis and macrophage production. CSF-1 also plays a role in
brain development (169) and in both male and female reproduction (for reviews, see
(170, 171)).

Of the many forms of osteopetrosis in humans, none has yet been proven
associated with mutations in the human CSFl gene. An autosomal dominant form of
osteopetrosis showed linkage to the chromosomal region in which human CSFl is located
(172), but mapping data did not confirm linkage with the C S F l gene (173). Nonetheless,
op mice and other osteopetrotic mutants have been very valuable in studying normal bone
biology as well as the pathophysiology of bone resorption disease in humans (for review,
see (174)). Much of the current knowledge of the physiological functions of CSF-1 has
been discovered through the study of osteopetrotic mice.

Defective lipopolysaccharide response !Tlr4b"d)
Bacterial endotoxin is a component of the cell wall of Gram-negative bacteria.
Also know as lipopolysaccharide (LPS), endotoxin elicits a potent inflammatory response
in most strains of mice as well as in many other mammalian species. More than 30 years
ago, it was discovered that C3WHeJ mice exhibited a defective immune response to
lipopolysaccharide (175-177), providing a model to study the physiology of the
endotoxin response as well as the genetic control of this response (178). The defective
allele for the endotoxin response was labeled Lpd, to distinguish from the normal allele,
LPs"
Endotoxin exerts its effect on multiple cell types in the immune system (179).
The normal endotoxin response includes mitogenic stimulation of B cells (180, 181),
proliferation of a subpopulation of T cells (182), macrophage cytotoxicity (183) and
inhibition of the phagocytic capacity of macrophages (184). C3WHeJ mice are defective
in these normal cellular responses to LPS. They do not produce the high levels of pro-

inflammatory cytokines that normally characterize the LPS response, and are therefore
more resistant to the lethal effects of LPS (185). As a result, however, C3WHeJ mice are
more susceptible to infection by Gram-negative organisms (186, 187). In 1977, it was
reported that C57BUlOCr mice also exhibit a defective LPS response (188), which was
mapped to the same locus disrupted in the C3WHeJ strain (189, 190).
The mutations responsible for defective LPS responses in mice were recently
found to disrupt the Toll-like receptor-4 (Tlr4) gene (191, 192). Toll-like receptors play a
key role in the induction of the innate immune response, which is the first line of defense
against infectious organisms (for review, see (193, 194)). The family of mammalian
Toll-like receptors have significant homology to Drosophila Toll (195) (for review, see
(196)). TLR4 is a transmembrane protein that conveys signals which activate NF-KBto
promote expression of the genes involved in the LPS response (197). TLR4 appears to
function only in the LPS response pathway, so other immunological functions are normal
in ~psdmice.Mice with a targeted mutation of the 77r4 gene have a phenotype that very
closely resembles that of C3H/HeJ mice carrying the Lpsd allele (198). While both
C3WHeJ and C57BUlOCr mice have mutations in 77r4, differences had been observed
in levels of interferon (IFN)-y production between the two strains in response to various
microorganisms (199). This variation has recently been recognized as the result of a
second mutation in the C57BUlOCr strain, in the ZL-12Rb2 gene (200), which results in
deficient induction of IFN-y through the IL-12 receptor (201). Thus, C57BUlOCr mice
are even more resistant to the toxic effects of LPS than C3WHeJ mice.
In humans, exposure to inhaled endotoxin can cause various degrees of airway
inflammation and asthma (202). The observation that certain individuals are sensitive to

environmental endotoxin exposure while others are more resistant prompted the
examination of the genetic regulation of t h s response in humans. Screening of a group
of subjects for both TLR4 mutations and degree of responsiveness to inhaled LPS
revealed that mutations in the human TLR4 gene were associated with airway
hyporesponsiveness to LPS challenge (203). Like the C3WHeJ mouse, humans with
reduced endotoxin responsiveness may be more susceptible to infection by Gramnegative organisms. Further examination of the role of TLR4 in LPS signaling may
disclose new approaches in the treatment of endotoxin mediated diseases.

Other mutations {microphthalrnia(Mi@). wasted (E~?fla2"").
hairless (hr)l
A number of other spontaneous mouse mutations have immunological
abnormalities as a component of a broader phenotype. One of these is microphthalmia
(mi) (204). Mutations at this locus affect pigmentation, secondary bone resorption, eye
development, hearing and immunological function (reviewed in (205)). The
immunological changes include reduced numbers and deficient function of mast cells and

NK cells (206) and osteoclast defects resulting in osteopetrosis (207). The mi gene has
been identified as a transcription factor in the basic-helix-loop-helix-leucine zipper
(bHLH-ZIP) family (208,209), now named Mi& whlch regulates transcription through
binding to specialized motifs found in melanocyte specific promoters. Recent studies
suggest that the immunological defects may be due both to a defect in the bone marrow
microenvironment (2 10) and to intrinsic cellular abnormalities (2 11 , 212). See (2 13,
214) for reviews of the role of MITF protein in melanocyte signaling and development.
Mutations in human MZTF have been found associated with Waardenburg syndrome

(WS) type II (215,216). WS type I ( O m 193500) and type III (OMIM 148820) are
caused by mutations in the PAX3 gene (217) which has been shown to regulate MZTF
gene expression (2 18).
Mice homozygous for the wasted (wst) mutation were noted for their neurological
phenotype. Characterized by development of tremors and ataxia beginning at about 21
days of age, followed by weight loss, progressive paralysis and lymphoid hypoplasia, wst
mice die shortly after weaning (219). The immunological abnormalities of wst mice
include increased sensitivity of hematopoietic cells to the cytotoxic effects of ionizing
radiation (219,220), defects in secretory Ig responses (221,222), disproportionate T-cell
subsets with abnormalities in cytokine levels (223) and sensitivity of thymocytes to
apoptosis (224). The wst mutation is caused by a deletion in Eefla2 gene encoding an
isoform of eukaryotic translation elongation factor la (EFla) (225). Eefla2 is expressed
only in brain, heart and skeletal muscle, and plays a role in protein synthesis in
mammalian cells (226)(for review, see (227)). The neurological phenotype in wst mice is
presumably related to defects in protein translation in the absence of EFla2 in brain,
heart and skeletal muscle of these mice. However, questions still remain as to how loss
of this protein can cause the immunological deficits seen in wst mice, since the protein
has not been detected in splenic tissue of either mice or rats (225). Although wst was
originally proposed to be a model of ataxia telangiectasia (AT) (219,228,229), AT is
now known to be associated with mutations in the human ATM gene (230). The human
homologue of the wst gene, EEFlA2, has been identified and sequenced (23 I), but there
is currently no known disease caused by mutations of this gene in humans.

The most apparent feature of the hairless (hr) mutation is total loss of hair
beginning at 3 - 4 weeks of age (232-234). In addition to alopecia, hr mice also have age
related immunological defects and a high incidence of thymic lymphoma (235-237) (for
review, see (238,239)). There are a number of different hr alleles (81). The wild type
gene encodes a predicted 1182 amino acid protein, 'HR', containing a zinc finger domain
with a 4-cysteine motif (240). The hr gene is widely expressed, and it has been
speculated that the HR protein may act as a transcription factor (240); however, its true
functions have not yet been resolved. Although thymic defects have been reported in hr
mice, no evidence of hr protein expression has been detected in the thymus (241).
Mutations of the human HR gene have been found in individuals with congenital atrechia
with papules (242-245). This disorder is characterized by complete hair loss and papular
lesions similar to those seen in mice homozygous for the rhino allele of hairless (hJh);
however, immunological abnormalities have not been reported in these patients. The
molecular basis of the hairless mutations and currently known functions of the hr gene in
both humans and mice have been reviewed recently (246-248).

Motheaten (Hcph")
The original motheaten (me) mutation occurred spontaneously on the inbred
C57BW6J background (249). Homozygous me mice are severely immunodeficient,
express high levels of serum autoantibodies (250-253) and die at approximately 3 weeks
of age from inflammatory lesions in the lungs and elsewhere. A second mutation at this
locus, 'viable motheaten' (me"), was reported in 1984 (250). Homozygous mevmice have
a similar but less severe phenotype, with a lifespan of approximately 9 weeks. The

longer lifespan of mevmicein comparison to me mice allowed more extensive study of
the nature of the mutation.
In 1993, the motheaten mutations were determined to be in the hematopoietic cell
phosphatase (Hcph) gene (254,255). The Hcph gene encodes the Src homology region 2
(SH2) domain-containing protein tyrosine phosphatase- 1 (SHP- 1) (256,257), which
functions as a negative regulator of signaling through a number of hematopoietic growth
factor receptors. SHP-1 exerts its negative regulatory role in hematopoietic cell growth,
dfferentiation and activation by dephosphorylating receptors, such as CD72, receptorassociated tyrosine kinases such as ZAP-70 or Jak2, and other signaling molecules
recruited through adaptor proteins such as Grb-2. (For a thorough review of SHP-1
signaling see (258)). SHP-1 has also recently been found to play a critical role in the
induction of apoptosis and cell cycle arrest in response to y-irradiation (259). The
phenotypic differences between the two allelic mutations at the me locus are due to a
variation in expression levels of the SHP-1 protein. The me mutation results in the total
absence of SHP-1 protein due to creation of a premature termination codon, while the mev
mutation (HcphmV)results in a significant reduction in SHP-1 activity due to the
generation of several alternative splicing sites.
Although the motheaten mutations are not a model for any known human disease,
they provide a valuable resource for the study of the role of a specific protein tyrosine
phosphatase (PTP) in the development and regulation of the immune and hematopoietic
systems. Studies of motheaten mice have provided insight not just into the function of
the SHP-1 phosphatase but into the general function of phosphatases and their integral
role in regulating an enonnous variety of cell signaling cascades and cell functions (258).

The human homologue of the mouse Hcph gene is called PTPN6 (260). No known
heritable mutations exist in human PTPN6. If germ-line mutations in this gene do occur
in humans, they may well result in embryonic lethality. Recently, however, aberrant
SHP-1 expression has been associated with a variety of human cancers. An errant splice
product of PTPN6 has been found in human myeloid leukemia cells (261). This posttranscriptional processing error is thought to result in a functional haplo-insufficiency of
SHP-1 protein, possibly contributing to leukemogenesis (261). SHP-1 expression is
absent or significantly reduced in many human T-cell lymphomas as a result of a
transcriptional block caused by methylation of the SHP-1 promoter (262). The absence
of SHP-1 protein is associated with constitutive activation of the interleukin 2-receptor
(LL-2R) -associated JakISTAT pathway and may contribute to the malignant
transformation human T cells (262). Defective expression of SHP-1 has also been
implicated in the pathogenesis of polycythemia Vera (263), and up-regulation of SHP-1
expression has been found associated with human breast cancers (264).

Conclusion
Determination of the molecular bases of mouse immunological mutations has
increased the understanding of the mechanisms of disease and aided in elucidating the
roles of these genes in the intact immune system. Certain of these immunological
mutations serve as homologues for human immunodeficiency and autoimmune diseases
(70, 81,265). Although the pathological changes related to these mutations may be
affected by physiological differences between mouse and man, the mouse models provide
an invaluable resource for biomedical researchers. Continued studies of new

immunological mutations at The Jackson Laboratory and elsewhere will likely lead to
further insights into the fundamental aspects of immune defense and expand the
knowledge of the immune system.

Chapter 2
SHP-1 PROTEIN TYROSINE PHOSPHATASE AND THE "MOTHEATEN"
MOUSE

Tyrosyl phosphorylation is a key regulatory mechanism involved in development
and function of the immune system. The intricate dance between tyrosine kinases and
phosphatases is crucial for maintaining balance in hematopoietic signaling. One misstep
can have severe consequences, resulting in autoimmunity, immune deficiency, or cancer.
As a result of the development of gene targeting techniques, there are now many mouse
models lacking specific components involved in regulation of immune function.
However, one of the first models for a specific tyrosine phosphatase deficiency was
found in mice with one of two spontaneous allelic mutations at the motheaten locus,
introduced in Chapter 1 of this manuscript.
As discussed in Chapter 1, mice carrying mutations at the motheaten locus are
deficient in SHP-1 (249,250,254). SHP-1 is a cytosolic protein tyrosine phosphatase

(FTP) that plays a crucial role in regulating proliferation, differentiation, and other
signaling processes in cells of the immune and hematopoietic systems. (For a review of
FTP's in signal transduction, see (266)). As a result of SHP-1 deficiency, mice
homozygous for the me or mev mutations have multiple hematological and
immunological defects that are discussed in detail elsewhere. In addition to being
valuable tools for the elucidation of SHP-1 function, studies using me and mev mice have
provided many insights into a wide range of signaling pathways and mechanisms
essential to maintenance of immune homeostasis (267).

SHP-1 functions primarily in the negative regulation of hematopoietic signaling
events induced by cytokines, growth factors and antigens (for review, see (258)). The 68

kD SHP-1 protein, (previously known as PTP-lC, HCP, SHP, SHPTPl and PTPN6),
contains two N-terminal Src-homology 2 (SH2) domains, a phosphatase catalytic region,
and a C-terminal region compatible with tyrosine phosphorylation (257,267) (Figure
2.1). The SH2 domains mediate the recruitment of the SHP-1 protein to phosphorylated
tyrosine residues within immunoreceptor tyrosine-based inhibitory motifs (ITIM's) in the
cytoplasmic regions of inhibitory receptors and co-receptors (see review (268)).
Structural rearrangement of the SHP-1 protein as a result of SH2 domain binding
activates the phosphatase catalytic domain (269), which dephosphorylates the intended
substrate, resulting in signal inhibition.
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Figure 2.1. Structure of SHP-1, showing the locations of the me and mevmutations.

SHP-1 has been shown to interact with a variety of both cytoplasmic and
membrane bound molecules in the regulation of B-cell signaling, including Lyn kinase,
CD22 (270), paired immunoglobulin-like receptor B (PIR-B) (271) and CD72 (272)
(Figure 2.2). The SHP-1 phosphatase is also involved in regulation of T cell receptor
(TCR) signaling function (273) (Figure 2.3). SHP-1 associates with CD5, which is a
transmembrane protein expressed on all T cells, and the B-la subset of B cells (274).
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Figure 2.2. Functions of SHP-1 in regulating signals through the B-cell receptor (BCR).
After BCR cross linking, the Src-family protein tyrosine kinase (PTK) Lyn has the
principal role in phosphorylation of tyrosine residues in both the immunoreceptor
tyrosine-based activation motifs (ITAMs) of Ig-do, as well as in the ITIMs of inhibitory
co-receptors (such as CD22, PIR/B, CD72 and FcyRIIB). Phosphorylation of ITIMs by
Lyn results in recruitment of SHP-1 through its SH2 domains. From its position at the
cell membrane, SHP-1 dephosphorylates activated PTK's and, by extension, PTK
substrates, resulting in inhibition of BCR mediated signals. (Figure based on (258)).
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Figure 2.3. Functions of SHP-1 in regulating signals through the T-cell receptor (TCR).
TCR engagement induces the transphosphorylation of the Syk-family PTK ZAP-70 by
the Src-family PTK Lck,which is associated with the CD4JCD8 co-receptor. The
consequent phosphorylation of ITIMs within inhibitory receptors such as KIR, Ly-49A
and CD5 results in recruitment of SHP-1 through its SH2 domains. SHP-1 can directly
associate with and dephosphorylate receptors or activated PTKs, or indirectly
dephosphorylate other signaling effectors such as SLP-76, through association with
adaptor proteins such as Grb2. (Figure based on (258)).

B-la B cells are often associated with autoimmunity in humans (reviewed in (275)), and
constitute a large percentage of total B cells in mev/mevmice. Chapter 3 describes studies
using mice homozygous for both the mev mutation, and a targeted deletion of the CD5
gene. These mice were developed to investigate the function of CD5-mediated signaling
in development of autoimmunity in the absence of SHP-1, as well as to provide insight
into the role of SHP-1 in regulating signals through the CD5 receptor.
Cells of the myeloid lineage are also dependent on SHP- 1 to regulate signals
through a multiplicity of receptors. In particular, macrophages from motheaten mice are
hyper-responsive to signals through receptors for granulocyte-macrophage colonystimulating factor (GM-CSF) (276) and macrophage colony stimulating factor (M-CSF or
CSF-1) (277), which direct proliferation and survival of cells of the granulocytemacrophage lineage and their progenitors. Heightened proliferation and accumulation of
myeloid-lineage cells is a characteristic of the motheaten mouse. Chapter 4 describes the
generation of mice transgenic for macrophage specific expression of a dominant negative
form of the SHP-1 protein, to investigate the cell autonomous effects of absence of
functional SHP-1 in macrophages and the effects of dysregulated macrophages on other
cell populations.
With the known role of SHP-1 as a negative regulator of cell signaling, it is
logical to postulate that loss of function of this regulatory protein could contribute to
malignant transformation, or that SHP-1 can act as a tumor suppressor gene. The
association of SHP-1 mutations with human cancers is discussed in the section on the
"motheaten" mouse in Chapter 1 (261,262). Studies are ongoing in our lab to identify
neoplasms arising in aged +/me and +/mev mice caused by loss of SHP-1 heterozygosity,

in order to substantiate the putative role of SHP-1 as a tumor suppressor gene (254).
Chapter 5 describes an osteogenic cell line derived from a spontaneous osteosarcoma that
arose in a 25-month old C57BU6J +/mev mouse. Preliminary studes of this malignant
neoplasm revealed that it was not caused by loss of expression of the SHP-1 protein.
However, the cell line by itself, or when used in transplantation experiments, has value as
a model for studying human osteosarcomas.
Several other molecules exist which share some structural homology with SHP-1,
includng SHP-2 (278) and an SH2 containing inositol polyphosphate 5'-phosphatase,
SHIP (279), both of which contain SH2 domains and may serve purposes similar to SHP1 in some incidences. However, it is evident by the severity of disease caused by SHP-1
deficiency that there are few, if any, precisely redundant molecules that may serve as a
substitute for SHP-1 in living systems. The known biological roles of SHP-1 are
multitudinous, yet many of its functions still remain a mystery. Further investigation into
the functions of this phosphatase may provide clues to expand the knowledge of a great
many signaling pathways involved in normal immunological function.

Chapter 3
ABSENCE OF CD5 DRAMATICALLY REDUCES PROGRESSION OF
PULMONARY INFLAMMATORY LESIONS IN SHP-1 PROTEIN-TYROSINE
PHOSPHATASE-DEFICIENT"VIABLE MOTHEATEN" MICE

Abstract
Mice homozygous for the viable motheaten (Hcphm+)mutation are deficient in
SHP-1 protein-tyrosine phosphatase, resulting in severe systemic autoimmunity and
immune dysfunction. A high percentage of B-cells in viable motheaten mice express the
cell surface glycoprotein CD5, in contrast to wild type mice that express CD5 on only a
small percentage of B-cells. CD5' B-cells have been associated with autoantibody
production. To determine the role of CD5 in the development of the inflammatory
disease in mev/mevmice, we created a stock of CD5-'-mev/mevmice. The longevity of
CD54mev/mevmice was increased 69% in comparison to mev/mevmice on a similar

B6;129 background. The increased lifespan was associated with a marked reduction in
pulmonary inflammation. Flow cytometry analysis of spleen cells from CD5'- mev/mev
mice at 9 - 12 wks of age revealed significant decreases in percentages of IgMlB220
double positive B-cells, Mac-11Gr-1 double positivecells and CD4'T-cells compared
with mev/mevmice. CD5-'- mev/mevmice also had significantly lower serum IgM levels in
comparison to mev/mevmice. Study of CD5'- mev/mevmice may provide further insight

'Modified from: Joliat W ,Lang PA, Lyons BL, Lynes MA, Yi T, Sundberg JP, Shultz LD. Absence of
CD5 dramatically reduces progression of pulmonary inflammatory lesions in SHP-1 protein-tyrosine
phosphatase-deficient viable motheaten mice. J. Autoimmun.In press.

into the role of CD5 in cell signaling and may help explain the observed association of
CD5' B-cells with autoimmune disease.

Introduction
Mice homozygous for either of the two recessive allelic mutations in the
hematopoietic cell phosphatase (Hcph) gene on Chromosome 6 are severely
immunodeficient, express high levels of serum autoantibodies (250-253) and die at an
early age from inflammatory lesions in the lungs and elsewhere. The Hcph gene encodes
the Src homology region 2 (SH2) domain-containing protein tyrosine phosphatase-1
(SHP-1) (256, 257), which is a negative regulator of signaling through a number of
hematopoietic growth factor receptors (258, 276, 280). The two mutant alleles of the
Hcph gene that arose spontaneously in C57BU6J mice are 'motheaten', (Hcphme,
abbreviated me) and viable motheaten (Hcphm+,abbreviated mev). The me mutation is
due to a cytosine deletion that results in the total absence of the SHP- 1 protein due to
creation of a termination codon. Death of me/me mice occurs at approximately 3 wks of
age. The mevmutation is a thymine to adenine transversion that results in creation of
alternative splicing sites and an 80% to 90% reduction in SHP-1 activity compared with
wild type mice. Homozygous mev/mevmice live to approximately 9 wks of age and are
thus the more commonly used model to study the consequences of deficiency in SHP- 1
protein tyrosine phosphatase (254).
In addition to autoimmunity and severe pulmonary disease, meV/mevmice have
many additional cellular abnormalities, including an increase in myelopoiesis (250, 281)
and multiple defects in lymphocyte development and function (282-285). A large

percentage of B-cells present in mev/mevmice express CD5 (286), which is normally
found only on T-cells and a small percentage of B-cells in wild type mice.
CD5 (Ly-1) is a monomeric 67-kD membrane glycoprotein expressed on all
mature T-cells and on a subset of B-cells, termed B-la cells. Classified structurally as a
member of the scavenger receptor family (287), CD5 consists of a cysteine rich
extracellular region and a cytoplasmic domain containing motifs compatible with
phosphorylation by tyrosine and serinelthreonine lunases (Figure 3.1). CD5 is part of the
TCR complex. It is expressed at low levels on immature, CD4TD8' thymocytes and is
upregulated in differentiated T-cells (288). Tyrosine residues within the CD5
cytoplasmic region are phosphorylated upon TCR stimulation (289). Recently, it was
reported that CD5 functions as a negative regulator of signal transduction through the
TCR, affecting thymocyte differentiation as well as mediating TCR signaling in mature
cells (290-292). CD5 has been found to be constitutively associated with SHP-1 in Jurkat
T-cells and normal phytohemagglutinin-expanded T-lymphoblasts (274), indicating that
the negative regulatory role of CD5 in T-cells may be medated through SHP-1.

Figure 3.1. Structure of CD5. The extracellular region contains three scavenger receptor
cysteine-rich domains, while the cytoplasmic region contains motifs compatible with
SerIThr or Tyr phosphorylation.

CD5 is associated with the B-cell receptor (BCR) on B-la cells (293). In wild
type adult mice, cells expressing CD5 constitute a significant percentage of the B-cell
population in the peritoneal and pleural cavities, while they are scarcely found in the
splenic B-cell pool (294). Although the function of CD5 on B-cells is poorly understood,
B-la cells, that express CD5, are associated with production of natural autoantibodies
(295), specifically of the IgM isotype (296). An increase in the number of B-cells
expressing CD5 is often associated with increased production of autoantibodies
(reviewed in (275)). In me/me and mev/mevmice, virtually all of the B-lymphocytes,
including the splenic populations, express CD5 (297). We theorized that CD5 deletion in
mev/mevmice would result in reduction of sytemic autoimmunity in these mice.
CD5 deletion in otherwise wild type mice does not interfere with the ability of
these mice to mount an efficient immune response (294). T-cells from C D ~ -mice
/
are

hyperreactive in response to TCR mediated signals in vitro (290), but this increased
reactivity has no apparent detrimental effect on T-cell function in vivo. Thus, mice
lacking CD5 are healthy and have normal distribution of lymphoid and myeloid cells. To
explore the effect that CD5 expression has on the autoantibody production and
inflammatory disease of viable motheaten mice, we crossed 1 2 9 - ~ d 5 ' ~(CD5.'
' ~ ~ ") mice
with C57BLl6J-mevmiceto create a stock of mice homozygous for the CD5 deletion and
segregating for the viable motheaten mutation. Comparison of the phenotypes of mev/mev
mice with or without CD5 revealed a marked role of this molecule in the development of
immunopathologic changes in mev/mevmice.

Materials and Methods
Mce
All mice were raised at the Jackson Laboratory (Bar Harbor, ME). 129-Cd5tm'Cg"
(CD5-I-)mice (294) were first crossed with heterozygous C57BU6J-+/mevmice.
Offspring were heterozygous for CD5-I-and were typed for the presence of the mev
mutation. Mice that were heterozygous for both the mevmutation and CD~'- were
intercrossed. Homozygous CD5-I-mice from these matings that were heterozygous for
the mevmutation were then intercrossed to create a B6; 129-CD54 mevstock in which the
CD5 null allele was fixed to homozygosity and the mice were segregating for the mev
mutation. Concurrently, 129P3lJ wild type mice were bred with C57BU6-+/mevmice in
order to produce mev/mevand +/? control mice on a matched segregating background that
expressed normal CD5 levels. Mice were typed for the CD5 null allele by PCR, using
primers for the inserted neomycin resistance gene (neol3: 5'-

CPGGGTGGAGAGGCTAIITC-3', neo14: 5'-AGGTGAGATGACAGGAGATC-3').
Determination of the genotype at the Hcph locus (mev/mev,+/mev or +/+) was also
conducted by PCR, using primers flanking the viable motheaten mutation (mev-F:5'CGTGTCATCGTCATGACT-3', mev-R:5'-AGGAAGPGGGGCTTTGCCGT-3').
Before electrophoresis, the amplification products were digested with RsaI to distinguish
among +/+, +/mev and mev/mevmice (298). Mice were housed in conventional pathogenfree animal facilities (299).

Histopathology
Groups of mice from 4 - 18 wks of age were euthanized by CO, asphyxiation.
Tissues were fixed in Fekete's acid alcohol formalin, embedded in paraffin, and sectioned
at 6 pm. Slides were stained with Mayer's hematoxylin and eosin (H&E) and Periodic
Acid Schiff (PAS) for histological examination. Immunohistochemistry was carried out
on lung and kidney sections using biotinylated rabbit anti-mouse Ig (DAKO, Carpinteria,
CA) for identification of immune complexes. Non-specific staining was blocked on
deparaffinized sections with peroxidase blocking reagent (DAKO). Tissues were then
incubated in primary antibody for 1 h at room temperature in a humidified chamber.
After three 5 min washes in PBS, tissues were incubated with avidinlhorseradishperoxidase conjugate for 45 min, followed by an additional trio of 5 min washes in PBS.
Tissues were then incubated in diaminobenzidine (DAB) for 5 min at room temperature
and washed in tap water for 5 to 15 rnin. Tissues were counterstained with hematoxylin,
dehydrated in graded ethanol, cleared in xylene, and coverslipped with Permount (Fisher
Scientific, Pittsburgh, PA).

Flow cytometric analysis
Monoclonal antibodies, conjugated with phycoerythrin, FITC or biotin, were used
for characterization of spleen cells from 9 - 12 wk-old and 15 - 18 wk-old mice.
Streptavidin-Red 6-70 was used as a secondary fluorophore for biotinylated antibodies.
The following antibodies were obtained from PharMingen, Inc. (San Diego, CA): antiCD4, clone RM4-5; anti-pan granulocyte (Gr-1), clone RB6-8C5 (300); anti-Mac-1,
clone MI170 (301); anti-CD23, clone B3B4 (302,303); anti-CD43, clone S7 (304-306);
and anti-CD19, clone 1D3 (307-309). Additional antibodies, as follows, were purified
from hybridoma cell lines as ascites; anti-CD3, clone 145-2C11 (310); anti-CD8, clone
53-6.72 (31 1,312); anti-IgM, clone R6-60.2; anti-B220, clone RA3-6B2 (313); anti-pan
macrophage, clone F4180; anti-MHC class I, clone MI142 (314); anti-MHC class Il, clone
M511 14 (315); anti-pan erythrocyte, clone Terl19 (316); and anti-CD5, clone 53-7.3
(31 1,312). Single cell suspensions were prepared from individual spleens by extrusion
of cells through Nytex 110 mesh bags (TETKO Inc., Elmsford, NY) into cold HBSS
containing 5% FBS and 0.1% sodium azide. Erythrocytes were lysed in buffered
ammonium chloride, and leukocyte populations were phenotyped as previously described
(297) using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). B-1 Bcells were identified by labeling cells with antibodies against IgM, CD19, and CD43.
Cells that were I ~ MCD19+,
~ ~ CD43+
~ , were considered B-1 B-cells (317, 318).

Ig levels
Levels of IgM, IgGl, and IgG3 in serum from 9 - 12 wk-old individual mice were
assayed by ELISA as previously described (297). Plates were coated with goat antimouse isotype specific antibody (Southern Biotechnology Associates, Birmingham, AL).
Alkaline phosphatase labeled goat anti-mouse K-chain (Southern Biotech) was used as
the detection antibody. Isotype specific standards (PharMingen) were run with each
assay. Plates were developed with p-nitrophenyl phosphate (Sigma Chemical Co., St.
Louis, MO) and read with the EL 3 12e Bio-Kinetics Reader (Bio-Tek Instruments,
Winooski, VT). Ig levels were determined from the standard curves.

Autoantibody determinations by ELISA
Circulating autoantibodies against histone proteins were determined using a
modification of a protocol described by Amoura et al. (319). In brief, individual wells of
96 well microtiter plates were first coated with 100 p1 of 2 pg/pl calf thymus histone
protein (Type IIS, Sigma) in PBS for 1 h at 37°C. The wells were then washed in an
automated microplate washer with PBS containing 0.25% Tween 20 (PBSIT~O),and then
blocked with 200 p1 PBS containing 1% BSA for 1 h at 37°C. The wells were washed,
and 100 p1 of each serum dilution was added to the appropriate wells. After incubation
for one additional hour at 37"C, the wells were washed three times, and then 100 pl of a
previously titered goat anti-mouse IgG (H+L)-alkaline phosphatase conjugate was added
to each well. Following incubation at 37°C for 1 h, the plates were washed, and then 100
p1 substrate (p-nitrophenyl phosphate, Sigma) dissolved at 1 mg/ml in diethanolamine
substrate buffer was added to each well. The rate of substrate conversion to colored

product at 37°C was monitored at 405 nm and recorded as mODImin. Autoantibodies
against double stranded DNA were detected according to a modification of a protocol
described by Zouali et al. (320). In brief, microtiter wells were coated with calf thymus
DNA at 10 pg/ml in TBS (10 mM Tris base, 150 mM NaCI, pH 7.4) for 2 h at room
temperature. Following this incubation, the plates were washed with PBS/T20 in an
automated microplate washer, and then processed as described above.

Hematology
Blood was collected from the retro-orbital sinus using heparinized capillary tubes.
Leukocytes and erythrocytes were counted using a model ZBI Coulter counter (maleah,

FL). Mean corpuscular volumes (MCVs) were calculated from the packed red cell
volumes and total RBC counts as previously described (250). Blood smears were stained
with Wright-Giemsa (Sigma) for examination of cells for morphological abnormalities.
Reticulocytes were counted using the ADVIA 120 Hematology system (Bayer Corp,
Tarrytown, NY). Confirmation of reticulocyte percentages was conducted manually
following staining with New Methylene Blue (NMB) stain (Mallinckrodt Baker Inc.,
Phillipsburg, NJ). Equal amounts of blood and stain were incubated together in a
capillary tube for 15 min and smears were prepared. The smears were then air-dried and
coverslipped with Permount (Fisher).

Spleen cell lysates and immunoblotting
Spleens were dissected from mutant and control mice at 5 - 8 wks of age and at
12 - 15 wks of age. Single cell suspensions were prepared after lysis of red blood cells

following established procedures (321). For irnrnunoblotting, the spleen cells were lysed
at 4°C for 30 min in cold lysis buffer (20 mM Tris, pH 7.4; 1 mM EDTA; 10% glycerol;
1% Triton X-100; 100 mM NaCl; 1 pg of leupeptin per ml; 1 pg of aprotinin per ml; 1
mM bezarnidine and 5 mM of iodoacetic acid). Cell lysates were clarified by

centrifuging for 10 min at 10,000g at 4" C. Protein levels were measures using the DC
Protein Assay (Bio-Rad, Hercules, CA). 20 pg of each sample was resolved in a 12.5%
SDS-PAGE gel and transferred to a nitrocellulose membrane (Schleicher & Schuell,
Dassel, Germany). The membranes were probed, as described previously (322), with
monoclonal antibody against phosphotyrosine (4G10, Upstate Biotechnology Inc., Lake
Placid, NY). Specific antibody signals were detected using an enhanced
chemiluminescence kit (ECL, Amersham Pharmacia Biotech, Uppsala, Sweden).

Bone marrow macrophage cultures
Bone marrow plugs from femurs and tibias were harvested by extrusion with cold
HBSS. Marrow plugs were disrupted by passage through a 25g needle. The resulting
single cell suspensions were washed 2x in sterile HBSS (Sigma), counted with a model
ZBI Coulter counter and resuspended in complete media (RPMI-1640 (Sigma) containing
2 mM L-glutamine, 10% FCS, 100 Ulml penicillin and 100 pglml streptomycin). A total
volume of 5 ml medium containing lo6cellslml was added to 25 cm2tissue culture flasks
with either 500 or 1000 unitslml of recombinant human (rHu) CSF-1 (Cetus) or
recombinant murine (rMu) GM-CSF (R&D Systems, Minneapolis, MN). Cultures were
incubated at 37°C in 5% CO, for 24 h to allow adherent cells to attach to the flask. The
non-adherent cells were transferred to duplicate flasks and cultured for 7 days with

periodic changes of media, maintaining the appropriate growth factor concentrations. To
recover adherent cells from flasks, medium containing any non-adherent cells was
removed and transferred to 50 ml tubes. The remaining adherent cells were washed 2x
with 10 ml warm HBSS, then incubated for 10 min with 10 ml2mM EDTAIPBS at 37OC.
Cultures were vigorously shaken to detach all adherent cells. The adherent cells were
then combined with the non-adherent cells in 50 ml tubes, washed 2x in HBSS and used
for FACS analysis as previously described. Preliminary FACS analysis of adherent and
non-adherent cells separately showed that they had similar staining profiles. In
subsequent FACS analyses, adherent and non-adherent were combined to increase the
numbers of cells available for analysis.

Statistics
All measures of variance are presented as SEM. Student's t tests were performed
to determine significance of difference of means. Significance was assumed for p values

< 0.05.

Results
Longevity
Thirty five B6; 129-CD5" mev/mevmice and an equal number of B6; 129-mev/mev
mice were monitored daily from three weeks of age (Figure 3.2). There was no
significant effect of gender on survival of these mice. The mean lifespan of B6;129CD5-I-mev/mevmice (162 +I- 10 d) was significantly increased in comparison to B6;129mev/mevmice, which had a mean lifespan of 89 +I- 8 d (p<0.0001). Our previous studies

revealed that C57BL6-mev/mevmice had a mean lifespan of 61 +/- 2.4 d (250), indicating
an effect of strain background on lifespan of these mice. All subsequent data compares
mev/mevmice, CDFLmev/mevmiceand wild type

+/+ controls on the B6;129 segregating

background. Although lifespan data has not been gathered on wild type B6;129 mice, the
average lifespan of C57BU6J mice is 800 days for males and 750 days for females (323).

Figure 3.2. Cumulative percent survival of B6; 129-mev/mevand B6; 129-CD5-I-mev/mev
mice as a function of age. Thirty-five male or female mice from each genotype were
monitored from 3 wks of age.

Immunopathology
In order to determine the effect of the CD5 null allele on the onset and progression
of the characteristic pathologic lesions of mev/mevmice, total necropsies were performed
on mutant (CD54 mev/mevand mev/mev)and control (CD5+ +I? and +I?) mice. All tissues
were examined histologically with a pathologist (J.P.S.) (324). Several striking
differences were noted in B6;129-CD5+ mev/mevmice when compared to B6;129-mev/mev
mice.
Development of pulmonary lesions was significantly delayed in CD5-Lmev/mev
mice in comparison to mev/mevmice. At 9 wks of age, this difference was evident grossly
at the time of necropsy. Lungs of mev/mevmice were mottled tan in color and firm, while
lungs of CDSJ-mev/mevmice resembled the lungs of wild type mice and were compliant
and evenly light pink in color. Histologically, the mev/mevmice developed earlier
acidophilic macrophage pneumonia (325,326), which progressed in severity more
rapidly than in CDSLmev/mev. Moderate disease was evident by 4 wks of age in mev/mev
mice and pneumonia was severe by 9 wks. Pulmonary lesions were minimal or absent in
CDYLmev/mevmice at 4 wks of age, and by 9 wks of age, only mild peribronchiolitis or
pneumonitis was observed (Figure 3.3). By 21 wks of age, most CD5-I-mev/mevmice
developed mild to moderate acidophilic macrophage pneumonia, while one CD5'mev/mevmouse necropsied at 43 wks of age had only mild pulmonary disease (data not
shown).
Spleens in CD5-/ mev/mevmice were markedly enlarged. Spleen weight expressed
as a ratio of spleen to body weight (S:BW)was increased 42% in CDYLmev/mevmice in
comparison to mev/mevmice (p<0.05) at 9 wks of age. The S:BWof mev/mevmice at 9

wks of age was increased almost 7 fold over a control group of

+/+ and +/? mice

combined (data not shown). The S:BWof both CD5" mev/mevmice and mev/mevmice
increased with age from 5 - 18 wks, while in +/? and CD5" +/? mice, this ratio did not
change considerably with age. The spleens in CDFLme'/mev mice at 9 wks of age had
poorly defined follicles and contained numerous multinucleated giant cells with abundant
cytoplasm. While the splenic follicles of mev/mevmice were poorly delineated, the
spleens lacked the extensive granulomatous lesions, consisting of multinucleated giant
cells, found in CD5-I-mev/mevmice (Figure 3.4). With increasing age, multinucleated
giant cells in CD5+ mev/mevmouse spleens became even more abundant, while the
relative number of these cells in spleens of mev/mevmice increased only slightly.
The livers in CD5'- mev/mevmice showed marked extramedullary myelo- and
erythropoiesis at 9 wks of age. In contrast, the livers in mev/mevmice exhibited only mild
extramedullary hematopoiesis (EMH), mostly myeloid in nature (Figure 3.5). By 16 wks
of age, EMH in livers of CD5%mev/mevmice had increased considerably, while EMH in
livers of mev/mevmice remained mild to moderate (data not shown).
CD5'- mev/mevmice did not develop hyperplasia of the non-glandular stomach, a
feature commonly seen in mev/mevmice at 9 wks of age (Figure 3.6 A). Inflammation of
the glandular stomach was observed in both CD5" mev/mevmice and mev/mevmice. Renal
glomeruli of CD5" mev/mevmice were enlarged and increased in cellularity at 9 wks of
age, suggesting a mild membranoproliferative glomerulonephritis. The mev/mevmice
exhibited glomerulonephritis, but the condition was less severe (Figure 3.6 B). Immune
complexes were detected in the glomeruli of both CD5'- mev/mevand mev/mevkidneys by
PAS staining and by immunohistochemistry using anti-mouse Ig (data not shown).

Blood urea nitrogen (BUN) levels were not significantly elevated in either CDSJ-mev/mev
or mev/mevmice ranging from 6 to 12 wks of age (data not shown).

Figure 3.3. Photomicrographs of lung of CD~-Imevlmevmice. Lung shows severe
eosinophilic macrophage pneumonia in mevlmevmice, in contrast to minor peribronchiolar
aggregation of lymphocytes in CD5-I-mevlmevmice and normal appearance in +/mevcontrol
mice. Tissue sections are from 62-64 day old B6;129 mice. All tissues were fixed in
Fekete's acid alcohol formalin and stained with hematoxylin and eosin.
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Figure 3.4. Photomicrographs of spleen of CD5-I-mev/mevmice. Spleens of mev/mevand
~ D 5 - lmevlmev
mice have poorly defined lymphoid follicles that are markedly depleted of
lymphoid cells. Spleens of CD5-I-mevlmevmice contain many multinucleated giant cells
(arrows) that are not present in mevlmevspleens. In +/mevmice, spleens reveal well-developed
follicles. Tissue sections are from 62-64 day old B6;129 mice. All tissues were fixed in
Fekete's acid alcohol formalin and stained with hematoxylin and eosin.

Figure 3.5. Photomicrographs of liver of CD5-'- mevlmevmice. Livers of mevlmevmice
exhibit mild extrarnedullary hematopoiesis, mostly myeloid in nature. In contrast, high
levels of extramedullary myelo- and erythropoiesis are evident in livers of CD5'- meVhev
mice. The +/mev livers appear normal. Tissue sections are from 62-64 day old B6;129
mice. All tissues were fixed in Fekete's acid alcohol forrnalin and stained with hematoxylin
and eosin.

Figure 3.6. Photomicrographs of kidney and stomach of C D ~ "mevlmevmice. A) Renal
glomeruli of CD5-Lmevlmevmice are enlarged and increased in cellularity, suggesting of a
mild membranoproliferative glomerulonephritis. The mevlmevmice show less severe
glomerulonephritis. B) Hyperplasia of the non-glandular stomach commonly seen in mevlmev
mice is not present in C D ~ - I -mevlmevmice. Tissue sections are from 62-64 day old B6;129
mice. All tissues were fixed in Fekete's acid alcohol formalin and stained with hematoxylin
and eosin.

Flow cytometry analyses of cell ~opulations
The observed splenomegaly in CD5&mev/mevand mev/mevmice was accompanied
by a significant increase in total numbers of nucleated cells in the spleen in comparison to
CDSd +I? and +I?mice, respectively (pd.05). Average numbers of nucleated
splenocytes in CDSJ- mev/mevwere increased in comparison to mev/mevmice, but the data
were not statistically significant. An elevation in the number of splenic myeloid cells
contributes to the splenomegaly observed in mev/mevmice (250). While an increase in
ratio of spleen weight to body weight (S:Bwt)was observed in CD5-I. mev/mevmice in
comparison to mev/mevmice, the reduction in severity of acidophilic macrophage
pneumonia observed in CD5-I-mev/mevmice suggested a general decrease in myeloid
cells numbers. To determine the proportions of cell populations present in the spleens of
CD5&mev/mevmice, flow cytometric analysis was performed.
Percentages of splenic Mac-1' Gr-1' monomyeloid cells were significantly
reduced in CD5-/ mev/mevmice compared to mev/mevmice, as were percentages of IgM'
B220' B-cells and CD3' CD4'T-cells (Table 3.1). However, CD5" mev/mevmice had a
significant increase in percentages of splenic Terl19' erythrocyte precursor cells
compared to mev/mevmice, suggesting that the augmented splenomegaly in CDSJmev/mevmice is a result of an increase in erythropoiesis.

Table 3.1. Flow cytometry analyses of spleen cells from 9 - 12 wk-old B6,129-CD5"
mev/mevmice.

-

Cell Population

B6;129
mev/mev

B- 1 cellst (as % of
total B-cells)
Ter 119'
12.6 _+ 2.9

-

-

-

B6;129
CD5-I-mev/mev

B6;129

B6; 129
CD5'- +/?

56.2 f 7.8*

2.2 f 1.1

+/?

-- -

2.2 f 0.8

Data are expressed as a mean percent f SEM {n = 6 for B6;129-CD5&mev/mev;n = 5
for B6;129-mev/mev;n = 4 for ~6;129-CD~"'+/? and B6;129-+/? ) {t B-1 cells were
identified as I~M'@",
CD19', CD43') { * indicates significant (p < 0.05) difference in
spleen cell populations between CD5'- mev/mevand mev/mevmice)
Mean # of
nucleated spleen
cells x lo8

3.4 f 0.6

4.4 f 0.7

1.7 f 0.3

1.1 f 0.1

To determine whether CD5 is necessary for development of B-1 cells, percentages
of these cells were determined using antibodes against IgM, CD43, and CD19.
Percentages of IgM' B220' B-cells that had a B-1 phenotype did not vary significantly
between C D 9 mev/mevmice and mev/mevmice (Figure 3.7), indicating that CD5
expression is not required for development of the B-1 cell population.

Figure 3.7. Flow cytometry analysis of B-1 B cells in spleens of CDYLmev/mev,
mev/mev,and +I? mice. Panels on the left show percentage of IgM' cells. Panels on the
right show percentage of I g M ~
cells that are CD43'1CD23-, an expression pattern
characteristic of B-1 B cells.

Total nucleated cell numbers in the spleen did not change significantly with age in

CD5'- mev/mev,mev/mev,CDS4 +I? or +I? mice. The only significant change in
percentages of spleen cell populations in CD5+ mev/mevwith age was a decrease in the

percentage of Mac-1' Gr-1- cells (p<0.05) in 15 - 18 wk-old mice in comparison to 9 12 wk-old mice (data not shown). In contrast, several significant differences were seen
when comparing spleens from 9 - 12 wk-old mev/mevmice to spleens of 15 - 18 wk-old
mev/mevmice. Percentages of CD3' CD4' T-cells, Mac-1' Gr-1' cells and IgM' B220' B-

cells were lower in 15 - 18 wk-old mev/mevmice when compared to 9 - 12 wk-old
mev/mevmice (p<0.05), while the percentage of Terl19' cells was increased (p<0.01)

(data not shown).

Peripheral blood analysis
Analysis of reticulocyte levels in peripheral blood using the Advia 120
Hematology Analyzer showed a significant increase in reticulocyte percentages in CD5-'mev/mevmice when compared to mev/mevmice (p<0.05) (Table 3.2). Reticulocyte

percentages of both mev/mevand CD5" mev/mevmice were significantly higher than in
wild type controls (p<0.05). Reticulocytes were also examined in smears of blood
stained with NMB, as described (Figure 3.8). This data reflects the results found using
the Advia 120 Hematology Analyzer.

%

Fignm 3.8. New methylene blue (NMB) staining for reticulocytes. Reticulocytes
contain RNA, which precipitates in NMB and is stained blue. Reticulocytes have discernible
blue granules (arrows). A manual reticulocyte count may be done by counting red cells in
a smear of new methylene blue stained blood and calculating the percentage of total red
cells that contain blue granules (reticulocytes).

In contrast to reticulocyte numbers, peripheral blood red cell numbers were
significantly reduced in both CD5-/ me'/mev and mev/mevmice in comparison to wild type
(+/+ and +/?) controls at 9 - 12 wks of age ( ~ ~ 0 . 0 5Although
).
there was a significant

increase in numbers of Ter-119' splenic nucleated erythroid cells in CDYLme'/mev mice
in comparison to mev/mevmice (Table 3.1), there was not a corresponding increase in
peripheral erythrocyte counts in CD5" mev/mevmice (Table 3.2). Moreover, there were
no significant differences in peripheral erythrocyte or leukocyte counts between CD5'mev/mevand mev/mevmice, although the average erythrocyte and leukocyte numbers as
well as hematocrit percentages were slightly lower in CD5-I-mev/mevmice in comparison
to mev/mevmice. Hematocrit percentages of mev/mevmice were lower on average than
those of wild type (+/+ and +/?) mice, but the difference lacked statistical significance
by a small margin (p = 0.055). Although the decrease in hematocrit percentages of CD5'.
mev/mevversus mev/mevmice was also not statistically significant, CD5'- mev/mevmice
did have significantly lower hematocrits than

+/+ or +/? mice (p<0.0001). Erythrocyte

mean cell volumes (MCV) did not differ significantly in any of the genotypes studied
(data not shown). Peripheral blood leukocyte numbers were comparably increased in
both CDFLmev/mevmice and mev/mevmice compared to wild type controls. The majority
of these cells were monocytes and granulocytes (data not shown). There was no
significant difference in either leukocyte or erythrocyte numbers in CD5-I-+/? mice
versus wild type +/? mice.

Table 3.2. Peripheral blood analysis of 9 - 12 wk-old CD5-'-mev/mevmice.
Cell Population
Erythrocytes
(x lo9cellslml)
Leukocytes
(x lo6celldml)

B6;129
mev/mev

B6;129
CD5'mev/mev

B6; 129
+/?

B6; 129
CD5'- +/?

7.0 f 0.6

6.4 f 0.4

9.3 f 0.8

9.7 f 0.7

16.6 f 3.0

14.2 It 2.0

7.5 f 0.8

9.1 f 1.4

Hematocrit (%) 44.0 f 2.8

39.4 f 1.4

50.3 f 1.5

51.5 It 0.7

Reticulocytes
(as % of total
red blood cells)

30.3 f 5.2*

2.9 f 0.1

2.8 f 0.2

17.3 f 4.5

Data are expressed as stated f SEM (n >3 for reticulocyte percentages; n > 6
for all other assays.) { * indicates significant (p < 0.05) difference in peripheral
blood cell populations between CD5'- mev/mevand mev/mevmice}

Serum I? levels
B-cells in mev/mevmice are hyperresponsive to stimulation through the B-cell
receptor (BCR) (327). This hyperreactivity to BCR mediated signals in the absence of
SHP-1 helps explain the otherwise counter-intuitive observation that serum levels of IgM
and IgG in mev/mevmice are significantly higher than in wild type mice, whde their
mature B-cell numbers are reduced. Since CD5'- mev/mevmice have significantly fewer
B-cells than mev/mevmice, we assayed serum Ig levels in CD5" mev/mevand control mice
(Figure 3.9).

Figure 3.9. Serum immunoglobulin levels. Levels of serum IgM are significantly
reduced in CD5-'- mev/mevmice in comparison to mev/mevmice (p<0.05). Absence of CD5
did not result in a significant reduction of IgGl levels or IgG3 levels in CD~'-mev/mev
mice in comparison to mev/mevmice. CD5" +/? mice showed a consistent reduction in Ig
levels in comparison to wild type (+/?) mice. However, the difference was only
statistically significant when comparing IgGl levels of CD54 +/? mice versus +/? mice
with intact CD5.

IgM levels were increased over 30 fold in mev/mevmice when compared with wild
type (+/+ and +/me")mice. In C D ~ "mev/mevmice, IgM levels were 70% lower than in
mev/mevmice but still almost 10 fold higher than in wild type (+/+ and +/me") mice.
Although previous reports have indicated that serum IgGl levels in C57BU6J-mev/mev
mice are not significantly elevated over normal while serum IgG3 levels are significantly
elevated in comparison with littermate controls (297), we found the opposite in our

studies. IgGl levels were 2.5 times higher in the serum of mev/mevmice than in +/?
litterrnates. These levels were lower in CD5" mev/mevmice than in mev/mevmice, but the
change was not statistically significant. No significant variation was observed in IgG3
levels between mutant and control mice.
It is interesting to note that levels of IgGl were significantly reduced in CDSJ- +/?
mice in comparison to +/? mice with a functional CD5 gene. Production of IgGl is Tcell dependent and CD5 expression by T-cells may be required to induce class switching
or secretion of IgGl. Levels of IgM aid IgG3 were lower in CD5" +/? compared with
+/? mice, but the differences were not statistically significant.

Autoantibody assays
To assess the presence of autoantibodies in CDS1 mev/mevand mev/mevmice,
serum levels of anti-double stranded DNA (anti-dsDNA) and anti-histone antibodies were
assayed by ELISA (Figure 3.10). Levels of these autoantibodies were elevated in the
and mev/mevmice, when compared to wild type (+/+ and
lserum of both C ~ 5 - mev/mev
+/me? controls. In contrast to IgM levels, that were significantly reduced in CD5-I.
mev/mevmice when compared to mev/mevmice, levels of both anti-dsDNA and antihistone antibodies did not vary significantly between CD5-/-mev/mevand mev/mevmice.
Levels of anti-histone and anti-dsDNA antibodies in CD5'- +/? mice showed no variation
from +/+ and +/mevcontrols.

B

Itdilution

Anti-Histone

Itdilution

Figure 3.10. Autoantibody determination by ELISA. Data is expressed as an average
rate of substrate conversion in mO.D./min f SEM (n=4).

Anti-phosphotyrosine western blotting
Variation in levels of tyrosine phosphorylation between two experimental samples
can indicate a possible alteration in cell signaling. In order to explore whether the
pathological changes observed in CD5" mev/mevmice compared with mev/mevmice were
accompanied by a difference in tyrosine phosphorylation, we examined total splenic
protein by anti-phosphotyrosine western blotting (Figure 3.1 1). Spleen cell lysates were
analyzed from mice at 12 - 15 wks of age as well as from mice at 5-8 wks (data from
younger mice not shown). In mev/mevmice at 12 - 15 wks of age, there was an increase
in tyrosine phosphorylation of proteins in the range of 28 - 45 kd. Highly
phosphorylated proteins in this range were not seen in CD5'- mev/mevmice of any age,
nor were they seen in younger mev/mevmice.

Figure 3.11. Characterization of tyrosine phosphorylation of proteins in spleen cell
lysates. Spleen cell lysates from male C57BU6J-CD5'- mev/mevand C57BU6J-mev/mev
mice at 4 months of age were analyzed by SDS-PAGE/immunoblotting with antiphosphotyrosine antibody. The positions of protein size markers (kDa) are indicated on
the left. Arrows indicate bands that exhibit enhanced tyrosine phosphorylation in

.

C57BU6J-mev/mevmice in comparison to C57BU6J-CD5" mev/mevmice.

Bone marrow macrophage cultures
Further support of the hypothesis that CD5 on macrophages plays a role in the
development of the macrophage pneumonia seen in mev/mevmice required confirmation
of the presence of CD5 directly on macrophages. Takahashi et al. (328) reported
development of CD5 expression on macrophages in cell cultures grown with CSF-1 or

GM-CSF. To verify this, we established cultures of bone marrow cells from C57BU6Jmev/mevmice as well as from C57BU6J-+/? Controls and from C57BU6J-CD5-'- mice.
Cultures were grown in the presence of either Rhu-CSF-1 or Rmu-GM-CSF. Adherent
and non-adherent cells from cultures had similar cell surface marker expression profiles
and were pooled for analysis. Flow cytometric analysis revealed that both C57BU6J-+/?
And C57BU6J-mev/mevbone marrow contained cells that expressed CD5 after 7 days of
culture with either 500 or 1000 units per rnl of CSF-1 or GM-CSF (Figure 3.12). There
was no difference in percentages of CD5' cells with various amounts of cytokine, so
results were pooled. Table 3.3 shows the mean results of three separate experiments.
Following stimulation with GM-CSF, >90% of bone marrow cells that expressed CD5
were found to co-express Mac-1. Bone marrow from CDSJ- mice grown under similar
conditions, as expected, did not express CD5. Under all conditions, Gr-1 was expressed
on 4 . 3 % of CD5' cells, and <0.9% of CD5' cells expressed CD19 or CD3.

Table 3.3. Flow cytometry analysis of bone marrow cultures.
Cytokine
Genotype
% of total cells that are

CD5'

CSF-1

GM-CSF

+/?

mev/mev

6.1 & 1.1

5.6 2- 0.9

+/?

4.0

+ 2.7

mev/mev

+

9.7 2.7

% of CD5' cells that are

Mac-1'

+

Data are expressed as a mean percent SEM. (n > 5) (* indicates significant
(p-cO.01) difference in % of CD5' cells expressing Mac-1 between mev/mevcultures
grown with GM-CSF and +I? cultures grown with GM-CSF as well as +I? and mev/mev
cultures grown with CSF-I.)
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Figure 3.12. Expression of CD5 on bone marrow cells grown in culture for 7 days with
1000 units per rnl GM-CSF. Top panel shows expression of CD5 on mev/mevcells,

bottom panels shows lack of CD5 expression on CD5-'- cells. Dead cells were gated out
using propidium iodide exclusion. Live cells were analyzed for CD5 expression.
Numbers shown are percentages of CD5' cells.

Discussion
This study focused on the role of CD5 in imrnunopathologic changes in mev/mev
mice. Absence of CD5 expression in mev/mevmice resulted in significantly increased
lifespan and numerous phenotypic changes in comparison to mev/mevmice with an intact
CD5 gene. Although a significant decrease in serum IgM levels was seen in CD5'mev/mevmice, this was not associated with reductions in autoantibodies against dsDNA or
histone proteins, two autoantibodies frequently elevated in mev/mevmice. The increased
longevity of CD5" mev/mevmice was, however, associated with a marked delay in
development of acidophilic macrophage pneumonia in these mice when compared to
mev/mevmice. The reduced levels of macrophage infiltration in the lungs of CD5-'mev/mevmice were associated with a significant decrease in myeloid cell numbers in the
spleen. Although the reduced acidophilic macrophage pneumonia may be a consequence
of altered interactions of B- or T-cells with myeloid cells due to the absence of CD5 on
the surface of the lymphocytes, mature B- and T-cells are not necessary for the
development of pulmonary inflammation in viable motheaten mice (329). Thus, the
absence of CD5 function alone in either B- or T-cells would be unlikely to lead to such
dramatic reduction of lung lesions as well as reduced myeloid cell populations in CD54
mev/mevmice.
Recently, CD5 has been found to be constitutively expressed on a population of
macrophages in mev/mevmice (281). CD5' macrophages can be induced in the peritoneal
cavity of wild type mice by treatment with high levels of GM-CSF. This cytokine is
elevated in peritoneal fluid of mev/mevmice (328), and myeloid cells from mev/mevmice
show enhanced signaling through the GM-CSF receptor (276). Our observation that

CD5'- mev/mevmice have reduced numbers of splenic myeloid cells and less severe
myeloid cell mediated pulmonary lesions compared with mev/mevmice may indicate a
role for CD5 in response of cells to myeloid growth factors such as GM-CSF. We
confirmed the development of CD5' macrophages in cultures of bone marrow from both
mev/mevand wild type mice supplemented with either GM-CSF or CSF- 1, providmg

support for the hypothesis that CD5 expression is involved with development or
activation of macrophages through myeloid growth factor receptors. Although bone
marrow cells from CD5-'- mice grown in culture with GM-CSF or CSF-1 lacked CD5
expression, myeloid cell antigen (Mac-1 and Gr-1) expression profiles on these bone
marrow cells were similar to cells from mice with an intact CD5 gene (data not shown).
Additionally, no quantifiable or qualifiable differences were apparent in colony assays of

bone marrow cells from CD5'- mev/mevmice or mev/mevmice grown in methylcellulose
media with either CSF-1 or GM-CSF (data not shown). This data suggests that CD5 may
play a role in later stages of myelopoiesis.
For many years, the presence of a common progenitor for B-cells and
macrophages has been suggested (330-333). Reports of biphenotypic Blmacrophage
cells have appeared in current literature (334-336) and CD5' B-cells have been shown to
develop macrophage characteristics (337,338), often in association with B-cell
malignancy (339,340) (reviewed in (333)). It has been shown that treatment of wild type
mice with GM-CSF resulted not only in an increase in numbers of CD5' macrophages,
but also in an elevation in numbers of CD5' hematopoietic progenitor cells and CD5' Bcells (328), supporting the presence of a common precursor for CD5' (B-la) B-cells and
CD5' macrophages. Lack of CD5 on biphenotypic Blmacrophage cells or on

macrophages believed to have evolved from B-1 B-cells may contribute to the reduced
severity of lung lesions seen in CD54 mev/mevmice in comparison to mev/mevmice. CD5
expression may play a role in lineage commitment, possibly through altering responses to
growth factors as suggested above.
There are three reported ligands for CD5 that are expressed on B-cells. These
ligands include CD72, CD5 ligand, and cell surface Ig. Interactions between CD5 and
these ligands are thought to play a role in communication between T and B-cells. CD72
is expressed constitutively on B-cells (341,342), while CD5 ligand (CDSL, gp40-80) is
expressed on activated B lymphocytes in the spleen (343) and is constitutively expressed
on peritoneal B-cells and B lymphoma cell lines (344). Poposil et al. (345) suggested
that CD5 can also interact with certain sequences in the V, framework of cell surface Igs.
Ligation of T-cell surface CD5 to gp40-80 on B-cells has been implicated in the
stimulation of B-cell proliferation through the gp40-80 receptor (344).
Until recently, CD5 ligands were reported to be present only on B-cells.
However, several studies have now provided evidence that CD5 ligands are present on a
variety of cell types in addition to B-cells, indicating that the interaction of CD5 with its
various ligands may play a more diverse role in cellular communication than is currently
thought. Agostini et al. reported the presence of CD72 on alveolar macrophages isolated
from human sarcoidosis patients (346). A recombinant soluble protein based on the
human CD5 extracellular region has been reported to bind to a variety of cells of myeloid
as well as lymphoid origins (347), indicating the presence of a novel, widespread CD5
ligand. Just as CD5'B-cells also express CD72, it is possible that a CD5 ligand is
expressed on certain monomyeloid cells and that it may play a role in the activation of

these cells through binding with CD5. Alternatively, interaction of CD5 with an
unknown ligand could be involved in adhesion of monomyeloid cells to other cell types.
The extracellular region of CD5 is closely homologous to that of CD6 (348), a scavenger
receptor family member involved in cell-cell adhesion through its ligand, CD166
(ALCAM) (349, 350). Interactions of CD5 with as yet unidentified ligands may be
responsible for accumulation of macrophages in the lungs of motheaten mice due to
dysregulated adhesion rather than solely dysregulated proliferation of pulmonary
macrophages.
Red cells and mature myeloid cells arise from a common multipotential precursor,
termed CFU-GEMM based on the ability of these progenitor cells to form granulocyte,
erythroid, monocyte, and megakaryocyte colonies in culture in response to the
appropriate cytolunes. CFU-GEMMs can differentiate into either erythroid burst forming
units (BFU-Es) in the presence of erythropoietin (Epo), or into granulocyte/macrophage
colony forming units (CFU-GMs) in the absence of Epo but in the presence of myeloid
growth factors such as GM-CSF. Spleens of mev/mevmicehave previously been reported
to contain high numbers of CFU-GMs in comparison to wild type mice, while the
frequency of CFU-GMs in the bone marrow is similar in mev/mevand wild type mice
(282). SHP-1 is involved in the negative regulation of Epo mediated signals (351). Both
bone marrow and spleens of mev/mevmice contain increased numbers of erythroid
precursors (CFU-Es) in comparison to wild type controls. CFU-Es from mev/mevmice
are hyperresponsive to Epo and a subpopulation of mev/mevCFU-Es has lost their
dependence on exogenous Epo (282). The increase in red cell precursors with a
corresponding decrease in relative numbers of granulocytes in spleens of CD5" mev/mev

mice versus mev/mevmice suggests the possibility that CD5 plays a significant role in the
myeloid differentiation pathway in the absence of SHP-1. Dysregulated Epo signaling
resulting from the absence of SHP-1 accompanied by insufficient myeloid growth factor
mediated signals in the absence of CD5 could potentially explain the apparent shift from
myelo- to erythropoiesis observed in CD5-l mev/mevmice in comparison to mev/mevmice.
The lack of CD5 may cause changes in lineage commitment in the myeloidferythroid
branch of cellular development as a result of a reduced response to myeloid growth
factors.
Although CD5 has been reported to be a negative regulator of signaling through
both the T-cell receptor (290) and the B-cell receptor (352), earlier studies indicated a
costimulatory role for CD5 in TCR signal transduction (353-355). Recently, additional
studies have corroborated the reports of CD5 providing positive signals in both B- and Tcells, through a distinct cascade of second messengers including acidic sphingomyelinase
and protein b a s e C-4 (356). Our finding that proteins in the range of 28 - 45 kd
showed increased phosphorylation on tyrosine residues in spleens of older mev/mevmice
but not in CD5&mev/mevmice of the same age may provide additional evidence of a
significant role in signaling for CD5. In the absence of the negative regulatory effects of
SHP-1, the signals conveyed through CD5 may result in the phosphorylation of one or
more novel signaling molecules in the 28 - 45 kd range. Identification of these
molecules could help further elucidate the relationship between CD5 and SHP-1 and
facilitate the resolution of the pathways in which these molecules interact.
Clear examination of the role of CD5 in the development of viable motheaten
pathological lesions is problematic on the B6;129 segregating background. A

polymorphic variation between 129 and C57BU6J linked to the CD20 (Ms4a2) gene,
which maps near the CD5 locus, has been shown to affect peritoneal B-1 cell populations

(357). Although the phenotypic differences observed in B6;129-CD54 mev/mevmice in
comparison to B6;129-mev/mevmice do not appear to be related to reduced B-1 cell
numbers alone, the effect of strain specific polymorphisms is an important consideration
in analyzing any targeted mutation on a segregating background.
We have recently completed backcrossing of the CD5 mutation on to the

C57BL16J background (to NlO) and have developed a colony of inbred C57BU6J-CD5'mev/mevmice. Spleen cell lysates from C57BU6J-CD5-I-mev/mevand C57BU6J-mev/mev
mice were utilized in the a-phosphotyrosine western blots shown in Figure 3.1 1. This
experiment mirrored what was seen in extensive western blotting studies using B6; 129-

CD5-I-mev/mevmice and B6;129-mev/mevmice. We are currently in the process of
expanding our colony of C57BU6J-CD5'-mev/mev mice. With these mice, we will reexamine the imrnunopathologic changes observed in our previous studies using B6;129
mice, as well as continue our investigation into the signaling alterations suggested by our
reported western blotting results. Confirmation of the role of CD5 in immunopathologic
changes in mev/mevmice using inbred C57BU6J-CD5-I-mev/mevmice will mitigate the
complications of variability associated with background modifying genes and
polymorphic diversity.

Chapter 4
GENERATION OF C57BLI6J MICE CARRYING A TRANSGENE FOR
MACROPHAGE SPECIFIC EXPRESSION OF DOMINANT NEGATIVE SHP-1
(C453S)

Introduction
The protein tyrosine phosphatase SHP-1, encoded by the hematopoietic cell
phosphatase (Hcph) gene in mice (256,257), is a negative regulator of signaling through
a number of hematopoietic growth factor receptors (258,276,280). Much of the
knowledge of the function of SHP-1 has been gained through the study of motheaten and
viable motheaten mice. As previously discussed, mice homozygous for either of these
two recessive mutations exhibit severe immunodeficiency and autoimmunity, and die at
an early age from inflammatory lesions, encompassing accumulations of macrophages
and neutrophils in the lungs and elsewhere (250-253). These mice have many cellular
abnormalities, including an increase in myelopoiesis (250,281) and multiple defects in
lymphocyte development and function (282-285).
One of the challenges in the study of SHP-1 using motheaten mice has been
discerning the cell autonomous functional defects caused by the absence of SHP-1 from
the secondary effects of macrophages and neutrophils resulting in disregulation of other
cell populations. Previous attempts in our lab to transgenically rescue SHP-1 expression
in specific cell populations in motheaten mice have been constrained by findings that
cells overexpressing SHP-1 in these transgenic animals have a selective disadvantage in
proliferation compared with the dysregulated cell populations that lack functional SHP-1

protein. Conversely, transgenic mice expressing a dominant negative or catalytically
inactive form of SHP-1 under the control of cell specific promoters have been used
successfully to study the effects of the absence of SHP-1 activity in vitro on individual
cell types (358,359).
Both me/me and mev/mevmice exhibit a marked expansion in numbers of
monomyeloid cells. The importance of the SHP-1 phosphatase in regulating myeloid
signaling pathways is evidenced by the severe inflammatory condition characteristic of
motheaten mice. In order to dssect the cell autonomous defects caused by the lack of
SHP-1 in macrophages, as well as to observe the effects of dysregulated macrophage
populations on lymphoid and other myeloid cell populations, we created a mouse
transgenic for macrophage-specific expression of a dominant negative form of SHP-1.
SHP-1 mutant C453S cDNA has been used previously to produce a dominant
negative protein in transgenic studies (358-360). The basis of this catalytically inactive
dominant negative mutant was the identification of an essential cysteine residue at
position 453 within the catalytic domain of SHP-1 (361). This essential cysteine, when
mutated to a serine (Figure 4. I), results in a expression of a protein that can be recruited
through its SH2 domains to imrnunoreceptor tyrosine-based inhibitory motifs (ITIMS),
but has defective phosphatase catalytic activity. Binding of this inactive protein to SH2
domain docking sites and substrates effectively blocks recruitment of endogenous wildtype SHP-1 (361), resulting in inhibition of SHP-1 function.
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Figure 4.1. The dominant negative SHP-1 mutation C453S. The G

+ C transversion

changes the essential catalytic cysteine (TCG), to a serine (TCC), inhibiting the
phosphatase catalytic activity of the SHP-1 protein. This catalytically inactive form of
SHP-1 competes for binding sites with wild type SHP-1, effectively reducing the activity
of the wild type protein.

To Qrect expression of the SHP-1 C453S mutant to macrophages, the promoter
for c-fms was used. The c-fms gene encodes the cell surface receptor for macrophage
colony stimulating factor (CSF-1) (362, 363). CSF-1 is a cytolune required for the
proliferation and survival of cells in the mononuclear phagocyte lineage. Expression of
the c-fms encoded CSF-1 receptor (CSF-1R) is regulated by tissue specific promoters
(364). Expression occurs on macrophages as well as in the placenta during gestation.
The promoter used in these studies induces macrophage specific expression of CSF-1R

Materials and Methods
Construction of SHP-1 dominant negative transgene for expression in macrophages.
The pBluescript plasmid containing wild-type SHP-1 cDNA with a KT3 epitope
tag and human growth hormone (hGH) poly A sequence driven by the CDl l b promoter
was a gift from Dr. Taolin Yi (Cleveland Clinic Foundation, Cleveland, OH). The
macrophage specific c-fms (CSF-1R) promoter, (365) (in pBluescript) was a gift from Dr.
Alessandra D'Azzo (St. Jude Children's Research Hospital, Memphis, TN). The SHP-1KT3-hGH segment of the SHP-1 construct was excised using EcoH and was subcloned
into a p138 plasmid linearized with EcoRZ. The c-fms promoter was excised from pBS
with SpeZ and EagZ and ligated into the p138 plasmid containing the SHP-1-KT3-hGH
construct, which was linearized with XbaZ and NotZ. The QuikChange Site-directed
mutagenesis kit (Stratagene) was used to create a G to C transversion which changed the
essential catalytic cysteine to serine, producing a construct that will express a putative
dominant negative SHP-1 protein (359). Mutagenesis was performed according to
manufacturers instructions using the following primers: (5'-CCG ATG CCA GCG CTC
GAA TGC ACA ATG ATG G-3') and (5'-CCA TCA TTG TGC ATT CCA GCG CTG
GCA TCG G-3').

Transgenic mice
Transgenic C57BU6J mice were generated by standard methods by The Jackson
Laboratory's microinjection service. Potential founders were screened for the transgene
by PCR using primers specific for the second intron of the Hcph sequence (5'-TCC CTG
GGA GCT TCC TGG CTC-3' and 5'-GGT GGG GTC CGA GCA GTT CAG-3').

Amplification with the endogenous SHP-1 gene yields a product of 494 bp, while
amplification with transgenic SHP- 1 yields a product of 25 1 bp. Presence of the
transgene was confirmed using primers for human growth hormone (5'-CAT CCC TGT
GAC CCC TCC-3' and 5'-CTC CAA ACC ACC CCC CTC-3').

Hematoloy
Blood was collected from the retro-orbital sinus with EDTA coated capillary
tubes and placed directly into Isoton I1 diluent (Coulter). Hematologic values were
determined using the ADVIA 120 hematology system (Bayer Corp, Tanytown, NY).
Control C57BU6J mice were age and sex matched with each SHP-1 C453S transgenic
animal tested.

Culture of bone marrow macrophages
To expand bone marrow macrophage populations for analysis, bone marrow plugs
from femurs and tibias of transgenic and wild type mice were harvested by extrusion with
cold HBSS (Sigma). Marrow plugs were dsrupted by passage through a 25g needle.
The resulting single cell suspensions were washed 2x in sterile HBSS, counted with a
model ZBI Coulter counter. Cells were resuspended in complete media (RPMI-1640;
Sigma, containing 2 rnM L-glutamine, 10% FCS, 100 Ulml penicillin and 100 pglml
streptomycin and 50 pM 2-P-mercaptoethanol) containing 500 unitslml recombinant
human (rHu) CSF-1 (Cetus). A total volume of 5 ml CSF-1 supplemented medium
containing lo6cellslml was added to 25 cm2tissue culture flasks. Cultures were
incubated at 37°C in 5% CO, for 7 days with periodic changes of media, maintaining the

appropriate CSF-1 concentrations. Cells were lysed in the flask for western blotting as
described.

Irnrnunoblotting
Cultured cells were lysed for 30 minutes at 4°C in cold lysis buffer (50 mM Tris,
pH 8.2, 150 mM NaCl, 1% (Octylphenoxy)polyethoxyethanol (Igepal CA-630; Sigma),
plus 1 tablet Complete, Mini Protease Inhibitor Cocktail Tablet w/EDTA (Roche
Molecular Biochemicals) I 10 ml buffer. Cell lysates were clarified by centrifuging for
20 min at 10,000g at 4" C. Protein levels were measures using the DC Protein Assay
(Bio-Rad, Hercules, CA). 20 pg of each sample was resolved in a 12 % SDS-PAGE gel
and transferred to a PVDF membrane (Millipore, Bedford, MA). The membranes were
blocked in 5% dry milk overnight at 4" C, then incubated with rabbit anti-mouse SHP-1
for 1-2 hours at room temp, with shaking. Membranes were then washed 3 X 5 min with
TBS-T (TBS ~ 1 0 . 0 5 %Tween 20), incubated with HRP conjugated goat anti-rabbit ~ a b ~
at RT for 30 - 60 min with shaking, then washed 5 x 5 min in TBS-T. Specific antibody
signals were detected using an enhanced chemiluminescence kit (ECLp'"', Amersham
Pharrnacia Biotech, Uppsala, Sweden).

Results and Discussion
The transgene was constructed as described (Figure 4.2). Sequencing from the
carboxy terminal end of SHP-1 through to the hGH poly-A sequence revealed an error in
the original construction of the CDl lb1SHP-1-KT31hGH plasmid.

Figure 4.2. Construction of SHP-1 C453S transgene. Murine SHP-1-KT31hGH poly A
was excised from pBluescript with EcoRI and cloned into p138, linearized with EcoRI.
The CSF-1R promoter was excised from pBluescript with SpeI and EagI and was cloned
into the p138 plasmid containing the SHP-1-KT3-hGH construct, which had been
linearized with XbaI and NotI. Mutagenesis was performed on the final construct to
change the essential catalytic cysteine to a serine (see Figure 4.1). The resulting
transgene should express a dominant negative SHP-1 protein under control of the
macrophage-specific promoter of CSF1-R (c-hs).
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A fragment of SHP-1 consisting of base pairs 88 - 266 of the wild type protein was
present at the carboxyl terminal end of the SHP-1 transgene, apparently in place of the
KT3 epitope tag, since a KT3 sequence was not found. However, the full cochng
sequence of the SHP-1 gene was present. Absence of the KT3 tag raises a number of
challenges when trying to identify the transgenic protein in expression studies. Studies
using dominant negative proteins that retain structural similarity to their wild type
counterparts rely on an epitope tag to identify the transgenic protein by immunoblotting
(359,360,366). The SHP-1 C453S transgenic protein differs from the wild type SHP-1
protein by only one amino acid, and the c-fms promoter drives expression of the
transgene in cells that normally exhibit significant expression of endogenous SHP-1.
Without an epitope tag, demonstration of the successful expression of the transgene will
rely on an increase in SHP-1 expression levels in macrophages, altered phosphorylation
on tyrosine residues of SHP-1 substrates or functional studies.
Transgenic mice were made by conventional methods, and founders were
identified by PCR as described (Figure 4.3). From the first 34 possible founders, 4
females were identified as transgenic. Of the following 71 possible founders, none tested
positive for the transgene. A new batch of transgene DNA was submitted to the
institutional microinjection service for generation of additional transgenic mice. The 4
founders were mated to C57BU6J males. One female founder died unexpectedly at 12
weeks of age, having produced no offspring. Founder #6 and founder #25 have produced
offspring. The first litter of each of these founders contained transgenic mice. All
existing transgenic mice, both founders and offspring from first litters, were bled from
the retro-orbital sinus for peripheral blood analysis.

Figure 4.3. PCR typing of SHP-1 C453S transgenic founders. Lane numbers correspond
to both upper and lower panels. A) Typing using primers for SHP-1. Lanes 6 and 8
show the intense 251 bp band indicating presence of the transgene. Lane 19: dH20, lane
20: wild type DNA control. Amplification of a 251 bp band in wild type mice was
unexpected, so transgene presence was confirmed by further typing with primers for hGH
poly-A sequence. B) Typing with primers for hGH results in amplification of a 151 bp
band in mice carrying the SHP-1 C453S trangene (Lanes 6 and 8).

If the transgene was functional, and the SHP-1 C453S protein had a true dominant
negative effect, one would expect to detect an increase in percentages of myeloid lineage
cells in peripheral blood of transgenic mice. However, peripheral blood counts of
transgenic and non-transgenic mice were not significantly different (Figure 4.4). There

was no significant variation amongst mice carrying the transgene, so data from all
transgene positive mice were pooled for comparison to wild type.
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Figure 4.4. Peripheral blood analysis of SHP-1 C453S transgenic mice vs.
wild type C57BU6J mice. (n = 8)

Macrophages containing numerous functional copies of the SHP- 1 C453S
transgene should produce greater total levels of SHP-1 protein than wild type cells. To
examine SHP-1 expression levels in the cell population to which transgene expression
was directed, one transgenic offspring from founder #25 was sacrificed. Bone marrow
was collected from femurs and tibias and cultured with CSF-1 to expand bone marrow
macrophage populations. Analysis of these cultured cells by western blotting showed no
increase in SHP-1 expression between SHP-1 C453S and wild type cells (Figure 4.5).
These data suggest that the transgene is not functional in bone marrow macrophages
grown in the presence of CSF-1. However, without an epitope tag to distinguish between

SHP-1 C453S and endogenous SHP- 1, it is possible that the transgene is being expressed,

but does not result in a detectable increase in SHP-1 protein. However, there was also no
detectable difference in tyrosine phosphorylation levels in SHP-1 C453S bone marrow
macrophages versus wild type (Figure 4.6). This suggests that the presence of the
transgene does not result in alteration of SHP-1 phosphatase function.

Figure 4.5. Anti-SHP-1 western blot on bone marrow macrophage and spleen cell
lysates from a SHP-1 C453S transgenic and control mouse. Lanes 1 & 2 contain lysates
from bone marrow macrophages, lanes 3 & 4 contain total spleen lysates. Lanes 1 & 3
are SHP- 1 C453S Tgn, lanes 2 & 4 are wild type. 2 pg of proteidlane.

Figure 4.6. Anti-ptyr western blot on bone marrow macrophages of A) SHP-1 C453S
transgenic mice and B) C57BU6J control mice.

Preliminary studies of mice carrying a transgene for macrophage-specific SHP-1
C453S expression do not confirm a functional effect of the transgene. Our collaborator
(Dr. Taolin Yi) has recently developed a novel, more effective dominant negative SHP-1
mutant. Although we will continue to expand the current founder colonies of SHP-1
C453S, we will investigate the efficacy of this new dominant negative SHP-1 mutant for
use in any future studies using a transgenic approach to alter SHP-1 function in a cell
specific fashion.

Chapter 5
ESTABLISHMENT AND CHARACTERIZATION OF A NEW CELL LINE
(MOS-J) FROM A SPONTANEOUS C57BLl6J MOUSE OSTEOSARCOMA.~

Abstract
This chapter describes the establishment and characterization of an osteoblast-like
cell line derived from a spontaneously occurring chondroblastic osteosarcoma in a
C57BLJ6J mouse. The tumor line, MOS-J, forms solid tumors when injected
intramuscularly into irnrnunocompetent syngeneic hosts, mimicking endochondral bone
development. These transplantable tumors have the capacity to destroy and invade
existing bone, and invade vessels in close proximity to the tumor. In culture, MOS-J
cells form layers of pleomorphic cells with high mitotic activity. These cells have
marked alkaline phosphatase enzyme activity and form calcified foci in vitro that stain
with alizarin red. MOS-J cells also promote osteoclast development from normal bone
marrow. These characteristics indicate the potential utility of the MOS-J osteosarcoma
cell line as a model for the studies of human osteosarcoma and normal bone biology.

Introduction
In an effort to substantiate the role of SHP-1 as a tumor suppressor gene, our lab
maintains aging stocks of +/me and +/mev mice, monitoring tumor incidence, and
classifying and collecting samples of each neoplasm for analysis. A 25-month-old
female +/mev mouse that was part of this study developed a firm, palpable mass in the

right distal femur. The mass was identified histologically as a chondroblastic
osteosarcoma, a rare tumor in mice (367,368). Preliminary investigation of this tumor
did not support the hypothesis that it resulted from loss of SHP-1 heterozygosity.
However, the cell line derived from this tumor may have significant value as a model of
human osteosarcoma.
Osteosarcoma is a malignancy of bone that commonly affects adolescents and
young adults, accounting for approximately 20% of all primary malignant neoplasms of
the bone in humans (369). Treatment often includes amputation of the affected area and
adjuvant chemotherapy treatment. Despite aggressive surgical and medical therapies, 5year survival rates range from only 10 to 60 %.
Cell lines provide an important resource for investigating the pathophysiology of
many types of cancers. These lines can be used for in vitro study of the biological
behavior of cancer cells, including the basic mechanisms of oncogenesis, expression of
growth factors and receptors and assessment of cell sensitivity to anti-neoplastic agents.
Mouse cancer cell lines provide a valuable tool for in vivo study of in situ and metastatic
tumor cell behavior following injection of the cells into immunocompetent syngeneic
hosts or into immunodeficient mice.
Here we describe an osteosarcoma cell line derived from a primary spontaneous
mouse chondroblastic osteosarcoma (osteochondrosarcoma). This cell line has many
characteristics of osteoblast-like cells, and may be a useful model for the study of both
osteosarcoma and normal bone biology, both in vivo and in vitro.

Modified from: Joliat MJ,Lyons BL, Umeda S, Lynes MA, Shultz LD. Establishment and
characterization of a new cell line (MOS-J) from a spontaneous C57BU6J mouse osteosarcoma. In prep.

Materials and Methods
Source of cancer tissue
The MOS-J (Mouse Qsteogenic Sarcoma - Jackson Laboratory) cell line was
derived from a spontaneous chondroblastic osteosarcoma that arose in the right distal
femur of a 757-day old female C57BU6J mouse heterozygous for the viable motheaten
(Hcph"',

hereafter abbreviated me3 mutation. The mouse was euthanized by CO,

asphyxiation and the lesion was removed for examination. Minced pieces of the tumor
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were placed subcutaneously into ~ ~ ~ ~ l c ~ ~ ~ - ~ r k d c(hereafter
mice. Additionally, portions of the tumor were disaggregated into a single cell
suspension and cultured to establish the cell line. Other sections of the tumor were fixed
for histological analysis as described below.

Histopathology
Tissues were fixed and demineralized in Bouin7ssolution, or fixed in Fekete7s
acid alcohol formalin and demineralized using Cal-EX decalcifying solution (Fisher
Scientific, Fair Lawn, NJ). Tissues were then embedded in paraffin, sectioned at 6 pm
and stained with Mayer's hematoxylin and eosin (H&E) for histological examination.
Irnmunohistochemistry was carried out on serial tumor sections using mouse anti-alphasmooth muscle actin (Sigma) for identification of vessel wall invaded by tumor cells.
Non-specific staining was blocked on deparaffinized sections with peroxidase blocking
reagent (DAKO). Tissue'sections were then incubated in primary antibody for 1 hour at
room temperature in a humidified chamber, washed 3 x 5 minutes in PBS and then
incubated with biotinylated secondary antibody against mouse IgG2a isotype for an

additional hour. After another three 5-minute washes in PBS, tissues were incubated in
avididhorseradish-peroxidase conjugate for 45 min, followed by an additional trio of 5minute washes. Tissues were then incubated in diaminobenzidine (DAB) for 5 minutes at
room temperature and washed in tap water for 5 to 15 min. Tissues were counterstained
with hematoxylin, dehydrated in graded ethanol, cleared in xylene, and coverslipped with
Permount (Fisher Scientific, Pittsburgh, PA). Processing of tissues was conducted by
The Jackson Laboratory's Biological Imaging service.

Establishment of the MOS-J cell line
Immediately after removal of the original neoplasm, normal muscle, vascular
tissue, fascia, and fat were removed from the specimen and discarded. Fractions of the
tumor were minced and dispersed in complete media (cWMI: WMI-1640 (Sigma, St.
Louis, MO) containing 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 pglml
streptomycin and 50 pM 2-P-mercaptoethanol) in a 50 ml centrifuge tube. The resulting
single cell suspension was seeded in 25 cm2tissue culture flasks and incubated at 37' C
in humidified 5% CO,. Culture medium was replaced twice a week until cells reached
confluence. Cultures were exposed to trypsin-EDTA to release adherent cells from the
surface of the flask, then were washed with fresh medium and subcultured at a density of
2 x lo5cellslml under similar culture conditions.

Growth rate
To determine the rate of cell growth, cells were plated at 5 x lo3cells/cm2in 35
mm 6-well plates in minimum essential media containing 10% FBS. Each well had a

growth area of 9.4 cm2. At 2 , 3 , 4 , 5 , 6 , and 7 days of incubation, cells were trypsinized
and counted with a hemacytometer. Values are expressed as the mean number of cells f
SEM from six wells.

Cell culture characteristics
Cells from the parental line were maintained in cRPMI. For studies of the
characteristics of cells in culture, cells were seeded in a culture dish containing several
glass coverslips. At 2, 5 and 9 days, a single coverslip was removed from the culture.
Cells were fixed in methanol for 15 minutes, then stained with H&E, dehydrated through
a series of ethanols to zylene and mounted on a slide with Permount (Fisher).

Alkaline ~hosphatasedetection in situ
Cells were plated into 6-well culture dishes (Corning Costar, Corning, NY) at 5 x
105cellsper ml in a total volume of 6 rnl complete media per well. They were
maintained in a humidified, 5% CO, incubator at 37' C for 72 hours. NM 3T3 cells were
plated simultaneously and used as a negative control. After 72 hours at 37' C, the culture
dishes were placed on ice. The medium was removed and the cells were washed twice in
cold PBS. Cells were then fixed in the dishes for 20 min on ice with methanol. The
methanol was removed and cells were washed twice in PBS. A BCIPINBT (5-bromo-4chloro-3-indolyl phosphatelnitro blue tetrazolium) substrate kit for alkaline phosphatase
was used (Zymed, San Francisco, CA) to detect alkaline phosphatase activity. The
substrate solution was prepared as directed by the manufacturer and 5 ml was added to
each well. Color development was allowed to occur for 5 - 10 minutes at room

temperature, after which the substrate was removed and the cells were washed twice in
distilled H,O.

Alizarin red staining
Cells were grown on coverslips in a culture dish for 30 days in cRPMI. Presence
of calcium was assessed in cultured cells using a Dahl's method for calcium (370), with
modifications. Briefly, cells were fixed for 15 min in methanol, then air-dried. Cells
were then incubated for 10 minutes in a solution of 1% aqueous alizarin red, which had
been adjusted to a pH of 6.4 with 0.1% ammonium hydroxide. Cells were rinsed three
times in dH,O, counterstained in 0.2% light green for 15 seconds, and rinsed briefly in
dH,O. Finally, cells were dehydrated through a graded series of alcohols to xylene and
mounted using Perrnount (Fisher).

Support of osteoclastogenesis
C57BL16J bone marrow cells (2.5 x 104/cm2)were seeded simultaneously with
tumor cells (1 x 104/cm2)in 8 well LabTek chambers and 6 well plates, in RPMI-1640
(Sigma) containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 p g h l
streptomycin and 50 pM 2-P-mercaptoethanol, supplemented with 10 nM/L 1-a-25
dihydroxy (OH), Vitamin D, (Calbiochem, San Diego, CA). Cells were grown both with
and without 500 U/ml recombinant human (RHu) CSF-1 (Cetus, Emeryville, CA) added
to the medium to promote osteoclast growth. As a control, MOS-J cells and bone
marrow cells were each grown alone with CSF-1. Cells were stained for tartrate resistant
acid phosphatase (TRAP) using a leukocyte acid phosphatase kit (Sigma).

Oncogenicity in mice
Five male mice of each of the three strains (C57BL/6J, C57BU6J-Rag-I-'-, and
NOD-RU~-~
were
- ~ )injected in the quadriceps muscle with cultured tumor cells (1.3 x lo5
cellsl0.lml sterile PBS). Growth was assessed by radiographic examination at 2 and 6
weeks post inoculation. At seven weeks after injection, the primary mass was removed
from two mice in each group by aseptic surgical amputation of the affected limb, as
described below (Dr. B. Lyons). The remaining mice of each strain were euthanized and
necropsied. Grossly evident nodules and selected organs were prepared for histological
examination as previously described. Mice surviving amputation were assessed by
radiographic examination for evidence of recurrence or metastasis.

5
Ultrastructural studies were performed on specimens obtained from transplanted
neoplasms in BALBlcByJ-scid mice. Neoplasms were fixed in 2% glutaraldehyde in 0.1

M cacodylate buffer for 60 minutes. Samples were rinsed in 0.1 M cacodylate buffer for
15 minutes, then post-fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 15
minutes, dehydrated in a graded series of ethanols (50 - loo%), then passed through
polypropylene oxide as the intermediate solvent. Samples were re-embedded in 1:2
propylene oxide 1 Epon mixture for 4 hours, exposed to a 1:3 propylene oxide 1Epon
mixture, then transferred to a conical Beem capsule. One hour later, the cells were placed
in a dessicator and incubated overnight, then polymerized in a 60' C oven for 48 hours.
One to two mm sections were cut and stained with Toluidine blue and ultrathin (70 90nm) sections prepared from selected areas were mounted on copper grids. The sections

were stained with aqueous uranyl acetate and Reynold's lead citrate and were examined
using a transmission electron microscope (371).

Amputation of affected limb
Coxofemoral disarticulation (372) was performed to amputate the affected leg.
Mice were anesthetized using Avertin (250 mgkg body weight). Muscle and skin layers
were closed separately with absorbable sutures and the mice were kept in a quiet, heated
environment and monitored until ambulatory. This procedure was conducted by a
licensed veterinary surgeon, (B. Lyons, D.V.M.). The protocol was approved by the
institutional Animal Care and Use Committee (ACUC).

Results
Histopathology of the original tumor
The original tumor occurred spontaneously in the right &stal femur of a 25month-old C57BU6J +/mevfemale mouse. The mass was lobular in shape, firm and pale
white in color. Histological evaluation showed variably sized bundles and streams of
closely packed undifferentiated spindled cells with discernable cell borders, containing
numerous mitotic figures. These cells contained a moderate quantity of basophilic, finely
fibrilar cytoplasm. Nuclei were pleomorphic, oval to elongate, containing course and
finely granular heterochromatin. Scattered throughout the mass were areas of irregular,
often interconnecting trabeculae of osteoid, generally contiguous with large areas of welldifferentiated hyalin cartilage. Numerous multi-nucleated giant cells resembling
osteoclasts were observed within the trabecular regions of the neoplasm. This tumor was

interpreted to be a well-differentiated osteochondrosarcoma. No metastases were
observed in lung, liver or other organs.

Cell culture characteristics
Growth rate and morphology of MOS-J cells were examined in culture. Figure
5.1 shows the growth rate of MOS-J cells in MEM withlo% FBS. Under growth assay
conditions in 9.4 cm2wells, cells began to detach after 7 days. However, in 75 cm2
culture flasks, cultures have been maintained successfully without passage for > 2 months
with bi-weekly me&a changes. Cultured MOS-J cells form layers of large, closelyspaced, polygonal and elongated cells with random orientation, containing pleomorphic
nuclei and abundant cytoplasm pigure 5.2). Multiple mitotic figures are present as well
as individual cell necrosis characterized by pyknotic and karyorrhectic debris.

2001Growth rate

Day

Figure 5.1. Growth rate of MOS-J cells in culture.

Alkaline phosphatase activity
Alkaline phosphatase activity is a characteristic feature of osteogenic
differentiation of osteoblast-like cells (373). MOS-J cells showed marked alkaline
phosphatase activity by enzyme cytochemistry (Figure 5.3 A). Negative control NIH 3T3
cells under similar conditions showed no activity (data not shown).

Alizarin red staining
Alizarin red detects calcium deposition, which is a hallmark of ossification. Cells grown
in culture contained numerous foci that stained positive for alizarin red (Figure 5.3 B, C).
In the areas of darkest red staining, cells showed a circular pattern of aggregation.

Osteoclast growth assay
MOS-J cells promoted osteoclast growth in normal bone marrow cells (Figure 5.3

D). TRAP-positive cells were present in cultures containing MOS-J cells with normal
bone marrow cells. No quantifiable difference was seen in numbers of TRAP-positive
cells in cultures grown with or without CSF-1. No TRAP positive cells were seen in
CSF-1 supplemented cultures of tumor cells alone or bone marrow cells alone (Figure 5.3

E, F).

Oncogenicity in vivo
MOS-J cells form rapidly growing tumors when injected IM into
immunodeficient mice as well as in immunocompetent syngeneic hosts. At two weeks
post injection, radiodense lesions were visible in the muscle of all mice in the vicinity of
injection. In some cases, osteolysis was evident in the existing bone adjacent to the
lesion (Figure 5.4 B). At 7 weeks post injection, lesions were prominent, radiodense, and
involved the bulk of the adjacent bone (Figure 5.4 C). In all cases, the injection
ultimately resulted in one visible, palpable mass that was firm and occasionally multilobated.
Histologically, the neoplasms were generally fairly well demarcated and nonencapsulated, with cells on the perimeter resembling periosteum. Spindle-shaped cells
containing areas of osteoid trabeculae were interspersed with cartilaginous matrix (Figure
5.5 A). Basophilic chondroblasts were visible in areas of cartilage production. Regions

of well-mineralized neoplastic bone as well as reactive normal bone were present (Figure
5.5 A, B). Lytic lesions were evident in existing bone (Figure 5.5 C). With IM injection,

there was no evidence of metastasis, radiographically or histologically, even after
amputation of the affected limb. However, there were multiple sites within indwidual
tumors where neoplastic cells were seen in close proximity to or even penetrating or
obliterating the vessel walls and growing into the lumen of vessels (Figure 5.5 D, E, F).

Ultrastructural findmgs of transplanted tumors
Tumor cells include large, irregularly shaped nuclei containing marginated
chromatin and prominent nucleoli (Figure 5.6). The cytoplasm contained abundant rough

endoplasmic reticulum (rER) and mitochondria. In some areas of the tumor, irregular
electron dense granules resembling mineral deposits formed a halo-like pattern around
the nucleus in the cytoplasm (Figure 5.6 A). Other areas of the tumor were characterized
by an abundance of extracellular collagen fibrils (Figure 5.6 B).

Discussion
The MOS-J cell line was derived from a spontaneous chondroblastic
osteosarcoma in a C57BL/6J +/mev mouse. The mev mutation disrupts the structural gene
(Hcph) encoding SHP-1 protein tyrosine phosphatase, also referred to as hematopoietic
cell phosphatase. The tumor derived MOS-J cell line was first examined for loss of
heterozygosity of the wild type Hcph gene as part of a study of the putative role of Hcph
as a tumor suppressor gene (254). If SHP-1 does indeed function as a tumor supressor
gene, increased tumor rates would also be expected in heterozygous +/me or +/mev mice.
Tumors would be expected to arise from cell types in which SHP-1 is known to function
as a negative regulator, such as T, B, or myeloid cells, and these neoplastic cells would be
expected to have deficient SHP-1 expression. The discovery of a firm tumor associated
with the bone was unexpected in this study and was of particular interest. However,
preliminary studies do not support the possibility that this tumor was caused by loss of
expression of the SHP-1 protein (data not shown). Moreover, the cell line derived from
this tumor has an osteoblast-like phenotype, and it has been shown that normal
osteoblasts do not express SHP-1 (374). Nonetheless, many characteristics of the MOS-J
cell line suggest that it may have utility in the study of bone biology as well as
osteosarcoma biology and treatment.
The MOS-J cell line has an aggressive phenotype characterized by unrestricted
growth, but accompanied by numerous functional and histocytological features of normal
osteoblasts. Alkaline phosphatase enzyme activity, ossification both in vitro and in vivo,
and ability to promote osteoclast development in culture are all indicative of osteoblastlike function by the MOS-J tumor cells. These transplanted tumor cells mimic the

process of endochondral ossification in vivo. Presence of basophilic chondroblasts and
cartilaginous matrix within the tumor is similar to the histological variant of the human
conventional osteosarcoma described as chondroblastic osteosarcoma.
The derivation of this cell line from a spontaneous tumor in a C57BU6J mouse is
a particular advantage over osteosarcoma cell lines derived from other species, less
common mouse strains, or mice in which oncogenesis was promoted by insertion of an
oncogenic transgene. These cell lines are often limited to transplantation into
immunocompromised hosts. Certain transgenes that induce oncogenesis, such as the
SV40 large-T antigen, can be immunogenic (375,376). Transplantation of cells derived
from transgene induced tumors can result in tumor rejection by immunocompetent
syngeneic hosts. Conversely, MOS-J cells may be transplanted, without rejection, into
immunocompetent C57BU6J mice. Many strains of mice carrying targeted mutations or
transgenes related to bone and cancer biology are maintained on the C57BU6J
background (see (265)). Study of the behavior of MOS-J cells transplanted into mice
bearing one or more of these mutations may provide insight into important biological
interactions involved in tumor growth and metastasis or bone development and
maintenance.
MOS-J cells have many histocytological features of normal osteoblasts. They
support osteoclast development when cultured with normal bone marrow, suggesting that
these cells may be used in the study of intercellular interactions or the investigation of
factors produced by osteoblasts that control osteoclast dfferentiation and activation.
CSF-1 is essential for normal osteoclast development (377). The observation that MOS-J
cells promote osteoclast formation in vitro without the addition of exogenous CSF-1

suggests that the MOS-J tumor cells, like normal osteoblasts (378), secrete CSF-1.
Experiments using other osteosarcoma cell lines have demonstrated that normal
osteoblasts secrete Interleukin-11 (IT.,-

11) (379), and that hepatocyte growth factor (HGF)

can induce secretion of IL-11 from osteoblast-like cells (380). IL-11 stimulates
TRANCE (TNF-related activation-induced cytokine) expression on osteoblasts (38 I),
which is crucial to the stimulation of osteoclast differentiation and bone resorption (375).
The MOS-J cell line may be a valuable tool in further understanding the intricate
processes involved in skeletal development and restructuring.
Although evidence suggests that the neoplastic characteristics of MOS-J cells are
not associated with mutations in SHP-1, further molecular characterization of the MOS-J
cell line has not been conducted. There are a large number of genetic mutations known
to be associated with osteosarcoma in humans (for review, see (382)). Investigation into
the genetic abnormalities existing in this line may identify novel mutations that lead to
the development of osteosarcoma, or may reveal mutations already known to be
associated with human osteosarcoma, providing a direct model for the study tumor
development.
Transplanted MOS-J cells have the capacity to infiltrate adjacent bone following
intra-muscular injection, and appear to invade vessels at multiple sites within transplanted
tumors. However, metastases have not been found in other organs. It has recently been
shown that intra-tibia1 injection of the rat osteosarcoma cell line UMR 106-01 into
athymic mice can result in lung metastasis where alternate methods of injection using the
same cell line have failed to produce metastasis (383). A number of genetic variations
have been associated with metastatic potential in an osteosarcoma model system (384).

Isolation of a metastatic variant of MOS-J or development of an injection system that
promotes metastasis of the transplanted tumor would enhance the value of this cell line
for the study of genetic alterations associated with metastasis. However, we have
assessed the metastatic potential of MOS-J cells following intra-tibia1injection, and have
found no evidence of metastasis. Despite the fact that a metastatic variant of MOS-J has
not yet been identified, MOS-J cells may be valuable in comparative gene expression
studies with osteosarcoma models that do show evidence of metastasis, such as the
histologically and behaviorally distinct tumors that arise spontaneously in SV40 Tag
transgenic mice (385,386).

CONCLUSION

Mice with spontaneous genetic mutations have provided crucial tools with which
to develop our knowledge of normal and pathological biological processes. Studies using
mice carrying the motheaten or viable motheaten mutations have advanced the
understanding of numerous signaling pathways in the immune and hematopoietic
systems. Recently, SHP-1 has received significant attention for its role in development
of human cancers (261,262,264,387) and for its contribution to other diseases of
hematological and immunological dysregulation (263,388). Continued investigation into
the extensive signaling capacities of SHP-1 may lead to further insights into these
diseases and into the complex physiological processes involved in maintaining
homeostasis of the immune system.
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